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ABSTRACT 
Renal transplantation (RTx) is a treatment of choice for children with end-stage 
renal disease. Excellent short-term survival is followed by moderate long-term 
results, and a considerable number of kidney grafts fail over the decades. Chronic 
allograft injury (CAI) is a multifactorial entity that manifests as a progressive 
deterioration of glomerular filtration rate (GFR), and histopathologically as interstitial 
fibrosis and tubular atrophy (IF/TA). CAI leads slowly to graft dysfunction and graft 
loss.  
 
This thesis aimed to investigate potential biomarkers of CAI. Selected biomarkers 
reflect the consequences of post-transplant immune response or complications of 
immunosuppression. Post-transplant human leukocyte antigen (HLA) antibodies, 
immunohistochemical biomarkers, presence of anemia, low-grade inflammation and 
BK polyomavirus were analyzed to identify pediatric RTx recipients at risk for CAI. 
Understanding the effect of these post-transplant risk factors on allograft function is 
important for the adequate monitoring and early identification of graft failure.  
 
The study cohort included 240 pediatric kidney transplant recipients who underwent 
RTx in Finland between 1988 and 2014. Data were retrospectively collected from 
patient records, and biomarker analyses were performed on stored serum samples 
or allograft biopsies. Luminex assay was used to detect donor-specific HLA 
antibodies (DSA) and immunoperoxidase staining to detect biomarker expression in 
biopsies. Finally, immunoassay method was used to detect inflammation and 
anemia related biomarkers and polyomavirus in blood samples. 
 
HLA antibodies were detected in half of the routine follow-up samples of 123 
pediatric RTx recipients. One-third of the patients had DSA, mostly against class II 
antigens. Donor-specificity, as such, was not predictive of subsequent deterioration 
of allograft function, questioning the need for modifications of immunosuppression 
in otherwise stable patients. Immunohistochemical staining of 165 biopsies from 56 
patients revealed progressive IF/TA changes during the first 3 years post-RTx. 
Intense staining of collagen IV and vimentin associated with decreased GFR later 
on, although there was no additional prognostic value on graft function compared to 
routine IF/TA score. Post-transplant anemia and low-grade inflammation were 
common complications even years after RTx in 128 patients followed for a median 
of 10 years. Low Hb levels preceded IF/TA findings in protocol biopsies and 
associated with poor subsequent graft function. Anemia was not explained by low-
grade inflammation or erythropoietin deficiency, and appeared early, rather than as 
a consequence of poor graft function. Inflammatory markers did not show a 
significant association with GFR at any time. BK viremia was detectable in nine 
patients with a tendency for decreased long-term graft function. Polyomavirus-
associated nephropathy was detected in three patients. 
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The studied risk factors of post-transplant allograft nephropathy were rather 
common in this pediatric study population, but the clinical impact of a single 
biomarker on the long-term graft function was relatively minor. These findings 
support the follow-up of different pathophysiologic pathways in order to identify the 
high-risk recipients of CAI before the loss of graft function. 
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TIIVISTELMÄ 
Munuaisensiirto on käypä hoito munuaisten vajaatoiminnan loppuvaiheessa. Siirron 
jälkeinen ennuste on erinomainen, mutta pitkänajan ennustetta heikentää osalle 
potilaista kehittyvä munuaissiirteen krooninen vaurio ja siirteen vajaatoiminta, joka 
johtaa lopulta siirteen menetykseen vuosikymmenten kuluessa. Munuaissiirteen 
krooninen vaurio on monitekijäinen kokonaisuus, joka ilmenee munuaissiirteen 
toiminnan heikkenemisenä ja solutason muutoksina, kuten munuaiskudoksen 
arpeutumisena ja munuaistiehyiden surkastumisena.  
 
Tämän väitöskirjatyön tavoitteena oli tutkia munuaissiirteen kroonista vauriota 
kuvaavia biomerkkiaineita verestä sekä munuaissiirteestä otetuista koepaloista. 
Valitut merkkiaineet kuvastavat siirron jälkeisen immuunivasteen aktivoitumista ja 
seurauksia sekä hyljinnänestolääkitykseen liittyviä komplikaatioita. Tutkimme siirron 
jälkeisiä HLA (human leukocyte antigen) vasta-aineita ja immunohistokemiallisia 
kudosmerkkiaineita sekä matala-asteisen tulehduksen, anemian ja BK 
polyoomaviruksen (BKPyV) vaikutuksia munuaissiirteen toimintaan lapsipotilailla. 
On tärkeää selvittää siirron jälkeisten riskitekijöiden merkitys munuaissiirteen 
kroonisen vaurion kehittymisessä, jotta siirteen toimintahäiriölle alttiit riskipotilaat 
voidaan tunnistaa varhain.  
 
Tutkimusaineistossa oli mukana 240 lapsipotilasta, joille on tehty munuaisensiirto 
Suomessa vuosina 1988–2014. Seeruminäytteistä ja munuaissiirteen 
kudoskoepaloista analysoitiin siirteen vauriota osoittavia merkkiaineita 
retrospektiivisesti. Verinäytteistä analysoitiin luovuttajaspesifisiä valkosoluvasta-
aineita Luminex–menetelmällä ja anemiaa ja tulehdusmerkkiaineita immunologisella 
vasta-ainetunnistuksella. Immunoperoksidaasivärjäyksillä havainnollistettiin 
muutoksia munuaiskoepaloissa. Munuaistoiminnan mittarina ja 
pitkäaikaisseurannan vastemuuttujana käytettiin mitattua 51Cr-EDTA-puhdistumaa. 
 
HLA-vasta-aineita oli puolessa siirron jälkeisistä seurantanäytteistä. Kolmasosalla 
potilaista havaittiin luovuttajaspesifisiä HLA-vasta-aineita (DSA), jotka reagoivat 
pääosin HLA luokka II antigeenejä vastaan. DSA:n esiintyminen ei yksinään 
ennustanut tulevaa munuaistoiminnan heikkenemistä, mikä kyseenalaisti yksittäisen 
DSA löydöksen merkitystä ja tarvetta muuttaa hyljinnänestolääkitystä muutoin 
vakaavointisilla potilailla. Immunohistokemiallisista merkkiaineista kollageeni ja 
vimentiini olivat yhteydessä myöhempään munuaistoiminnan heikkenemiseen, 
mutta nämä merkkiaineet eivät tuoneet merkittävää lisää perinteisen Banff-
luokituksen ennustearvoon. Anemia oli yleistä vielä vuosia siirron jälkeen. Varhaiset 
matalat hemoglobiini-arvot edelsivät munuaissiirteen kroonisen vaurion 
ilmaantumista ja heikkenevää munuaistoimintaa. Myös siirron jälkeisen BKPyV 
viremian havaittiin liittyvän munuaistoiminnan hiipumiseen jo ennen 
kudoskoepaloissa havaittavaa polyoomavirusinfektioon liittyvää munuaistautia.  
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Väitöskirjatutkimuksen tulokset lisäävät tietämystä kroonisen munuaisvaurion 
riskitekijöistä munuaisensiirtolapsilla. DSA-vasta-aineiden, anemian ja matala-
asteisen tulehduksen ilmaantuminen munuaissiirron jälkeen oli yleistä, mutta vain 
anemialla  ja munuaiskoepalassa havaittavalla arpeutumisella todettiin selkeä 
ennustearvo munuaistoiminnan hiipumiseen. Yksittäisten merkkiaineiden kliininen 
hyöty munuaistoiminnan ennustajana on rajallinen, mutta löydökset tukevat eri 
patofysiologisten tekijöiden pitkäaikaisseurantaa munuaissiirteen krooniselle 
vauriolle alttiiden riskipotilaiden varhaiseksi tunnistamiseksi.  
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ABBREVIATIONS 
ABMR antibody-mediated rejection 
AR acute rejection 
AZA azathioprine 
BKPyV BK polyomavirus 
CAI chronic allograft injury 
CAN chronic allograft nephropathy 
CKD chronic kidney disease 
CAKUT congenital anomalies of the kidney and urinary tract 
CMV cytomegalovirus 
CNI calcineurin inhibitor  
51Cr-EDTA Chromium-51 labeled ethylenediamine tetraacetic acid 
CRP C-reactive protein 
CsA cyclosporine A 
CNF congenital nephrotic syndrome of the Finnish type 
DD deceased donor 
DSA donor-specific HLA antibodies 
dnDSA de novo DSA 
ECM extracellular matrix 
ELISA enzyme-linked immunosorbent assay 
EMT epithelial-to-mesenchymal transition 
EPO erythropoietin 
ESR erythrocyte sedimentation rate 
ESRD end-stage renal disease 
GFR glomerular filtration rate 
Hb hemoglobin 
HLA human leukocyte antigen 
hsCRP high-sensitivity C-reactive protein 
HUS hemolytic uremic syndrome 
IL-6 interleukin-6 
IF/TA interstitial fibrosis and tubular atrophy 
JCPyV JC polyomavirus 
LD living donor 
MFI mean fluorescence intensity 
MMF mycophenolate mofetil 
pmarp per million age-related population 
PTLD post-transplant lymphoproliferative disorder 
PyVAN polyomavirus-associated nephropathy 
RRT renal replacement therapy 
RTx renal transplantation 
Tac tacrolimus 
TCR T-cell receptor 
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1 INTRODUCTION 
Renal transplantation is a treatment of choice for children with terminal renal failure. 
The goal of transplantation is to improve the health and quality of life of kidney graft 
recipients. In the past 50 years, transplantations have improved from the early 
experimental operations to an optimal mode of therapy in adults and children with 
end-stage renal disease (ESRD). Already in the 1960s, the short-term results of 
kidney transplantations were promising, but the risks of operations raised questions 
about rationality, especially among young pediatric patients. The lack of adequate 
immunosuppression hampered long-term results. Since the early 1980s, the use of 
Cyclosporine A (CsA) has reduced acute rejection rates and improved the long-term 
outcomes dramatically. Improvements in immunosuppressive therapy have allowed 
pediatric ESRD patients to grow and develop normally (Papalois, Najarian 2001, 
Sundaram et al. 2007)  
 
In Finland, over 250 children and adolescents have undergone renal transplantation 
(RTx) at the Children’s Hospital in Helsinki since 1986. Every year, on average 10 
patients receive a kidney transplant, nearly half from a living donor (LD). The 
prevalence of pediatric patients on renal replacement therapy (RRT) in Finland is 
the highest (84.4 per million age-related population, pmarp) in the Europe. This is 
mainly due to the high incidence of the congenital nephrotic syndrome of the 
Finnish type (CNF); the first known, and the most common of the Finnish heritage 
diseases (Norio 2003).  
 
To date, pediatric kidney recipients have the best long-term graft survival among 
recipients of all age groups. Short-term survival is excellent due to advances in 
immunosuppression, histocompatibility testing, surgery and perioperative 
management, whereas chronic allograft injury (CAI) and premature graft loss limit 
the long-term results (Dharnidharka et al. 2014). Importantly, improvements in 
immunosuppression also predispose patients to adverse effects, and patients are 
more vulnerable to infections and malignancy, which further challenge the post-
transplant period.  
 
Clinical characteristics of CAI include slowly rising serum creatinine, proteinuria and 
hypertension (Pascual et al. 2002). Creatinine-based estimates of glomerular 
filtration rate (GFR) provide no insight into the underlying mechanisms of this clinic-
pathological entity, and are insensitive to moderate changes in graft function, which 
may delay the diagnosis of the allograft nephropathy (de Souza et al. 2015). Current 
recommendations highlight the importance of early detection and follow-up with 
biopsies, although possible interventions may have only limited effect (Weir, Wali 
2009). The main goal is to maintain long-term allograft function, especially among 
pediatric recipients with adult kidney grafts. This study aimed to identify the clinical 
relevance of early biomarkers of kidney allograft injury in pediatric RTx recipients. 
Review of the literature 
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2 REVIEW OF THE LITERATURE 
2.1 Kidney 
2.1.1 Kidney anatomy and function 
Kidneys are anatomically complex, bean-shaped organs in the retroperitoneal 
space. Microscopically, the structure relates closely to function (Figure 1). The main 
function of the kidneys is to maintain electrolyte and acid-base homeostasis and to 
remove excess water, salts and metabolic waste products from the blood to urine 
while restoring nutrients, glucose and amino acids back to blood (Moore, Dalley 
2006). Adult kidneys filter about 180 liters of primary urine through glomeruli each 
day, but after reabsorption in tubules and collecting ducts, only about 1.5 liters of 
urine is excreted. In addition, kidneys produce essential hormones and enzymes. 
Interstitial fibroblasts produce erythropoietin, a hormone responsible for red blood 
cell production, and juxtraglomerular cells secret renin, which regulates blood 
pressure.  
 
Figure 1 Schematic presentation of the kidney allograft in the right iliac fossa. In the renal cortex, 
each kidney contains roughly a million nephrons, which are responsible for ultrafiltration. 
Each nephron, the functional unit of the kidney, can be divided into glomerulus, proximal 
and distal tubule, loop of Henle and collecting duct. The hypertonic medulla contains the 
loops of Henle and collecting ducts, and is essential for reabsorption of water. Renal 
biopsy is required for the histological diagnosis of renal disease.  
2.1.2 Glomerular filtration rate  
Renal clearance occurs in kidney glomeruli. GFR is a volume of filtrate formed in 1 
minute corrected to the standard body surface area of 1.73 m2. GFR is accurately 
measured by plasma clearance of chromium-51 labeled ethylenediamine tetraacetic 
Review of the literature 
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acid (51Cr-EDTA) (Fleming et al. 2004). The advantages of measured GFR are 
evident, especially among transplant recipients with multiple confounders (i.e., 
uremia, muscle wasting effect of corticosteroids, medications) that affect serum 
creatinine levels, making the interpretation of estimated GFR challenging (Stevens, 
Levey 2009).  
 
Indirect assessment of GFR is more simple and common, and several algorithms 
exist based on the plasma creatinine value with specific modifications for children 
(Hoste et al. 2014, Hoste et al. 2015, Pottel et al. 2015, Vroling et al. 2016). 
Estimated GFR is rather insensitive to moderate changes of accurate GFR, and 
only a substantial (50%) reduction in renal function increases the creatinine level 
above reference ranges (Piepsz et al. 2001, Stevens et al. 2006).  
2.1.3 End-stage renal disease 
ESRD is a rare but life-threatening condition in patients with various kidney 
diseases (Harambat et al. 2012). The stages of chronic kidney disease (CKD) 
represent the level of kidney function (Table 1). Dialysis is an alternative 
replacement of organ function, which is a unique opportunity compared to other 
solid organ transplantations. Most ESRD patients need dialysis before receiving a 
kidney transplant. Active maintenance dialysis before transplantation improves the 
metabolic and nutritional status, and allows children with ESRD to grow and 
maintain renal function (Warady et al. 2014).  
 
Table 1. Stages of chronic kidney disease (CKD) (Karthikeyan et al. 2004) 
CKD stage GFR (mL/min/1.73 m2) Description 
1 90 + Normal kidney function 
2 60-89 Mild decrease in GFR 
3 30-59 Moderate decrease in GFR 
4 15-29 Severe decrease in GFR 
5 < 15 or on dialysis ESRD 
CKD, chronic kidney disease; GFR, glomerular filtration rate; ESRD, end-stage renal disease. 
 
The overall incidence of pediatric ESRD patients requiring RRT is approximately 5 
cases per million of the age-related population (pmarp) in Europe (Chesnaye et al. 
2014). In Finland, this number of new RRT patients per year is somewhat higher, 
around 9 pmarp (ESPN/ERA-EDTA registry report 2013), mainly due to the CNF, 
which accounts for the additional incidence to Finnish disease burden compared to 
the other European countries. These young patients, often under 2 years of age, 
require early dialysis at a median of 1.4 years before RTx (Laakkonen et al. 2008) 
to enhance growth, development and the quality of life (Jalanko et al. 2015). 
Review of the literature 
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2.2 Renal transplantation in children 
Kidney transplantation in children shares many aspects with transplantation in 
adults, i.e., surgery, medication, and acute rejection episodes (Dharnidharka et al. 
2014). On the other hand, transplantations in children are unique and differ in terms 
of the primary kidney diseases (structural and congenital diseases in children), 
recipient’s smaller size, and altered drug metabolism and pharmacokinetics. Also, 
primary viral infections, growth, and transition to adult care are specific topics 
among children (Dharnidharka et al. 2014).  
2.2.1 Recipient 
The major indications for RTx in children are different from those in adults (Figure 
2). Most pediatric RTx recipients have congenital anomalies of the kidney and 
urinary tract (CAKUT) or inherited disorders, whereas diabetic nephropathy, 
hypertension and autosomal dominant polycystic kidney disease are the most 
common indications in adult RTx recipients (Holmberg, Jalanko 2015, Chesnaye et 
al. 2014, Dharnidharka et al. 2014).  
 
Besides CAKUT, glomerulonephritis is the other common cause of renal failure in 
pediatric renal transplant recipients and affects more often older patients while 
younger ones are more likely to have hereditary or congenital disease. In Finland, 
RTx recipients have higher frequency (40%) of CNF (Figure 2), and patients require 
transplantation at a younger age compared to other Nordic countries (Jahnukainen 
et al. 2016). 
 
Figure 2 Etiology of end-stage renal disease (ESRD) in transplanted children in Finland, Europe 
and USA. CNF, congenital nephrotic syndrome of the Finnish type; HUS, hemolytic 
uremic syndrome; GN, glomerulonephritis; CAKUT, congenital anomalies of the kidney 
and urinary tract; FSGS, focal segmental glomerulosclerosis; Cystic, cystic kidney 
disease. 1 Children’s Hospital, Helsinki; 2 ESPN/ERA-EDTA registry (Chesnaye et al. 
2014); 3 NAPRTCS registry (NAPRTCS annual report 2014). 
Review of the literature 
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CNF is a Finnish heritage disease affecting 1 in 8000 live births (Norio 2003). In the 
Finnish patients, two main mutations (Fin-major, Fin-minor) appear in the NPHS1 
gene, which encodes an essential component of the glomerular filtration barrier, a 
protein called nephrin. Mutation in NPHS1 results in massive proteinuria (Holmberg, 
Jalanko 2014). CNF patients with severe proteinuria require pre-transplant 
nephrectomy and initiation of dialysis at the age of 6-9 months, and thus undergo 
transplantation under the age of two years (Jalanko et al. 2015). Infants (0- to 24- 
month-old children) account for one-third of the pediatric RTx recipients in Finland, 
compared to 5.5% in the USA where most (47%) of the recipients are adolescent at 
the time of RTx (NAPRTCS Annual Report 2014).  
2.2.2 Donor evaluation and surgery 
Similarly to recipients, kidney donors require pretransplant evaluation. Preoperative 
assessment of a living donor follows generally accepted criteria in order to minimize 
risks for the donor. Physical and psychological health, renal vascular anatomy and 
kidney function are crucial for optimal and safe transplantation (Harmath et al. 
2016). Moreover, careful selection of deceased donors ensures optimal graft quality 
and improves post-transplant survival (Israni et al. 2014). The demand for new 
kidney allografts exceeds deceased organ availability, resulting in an increase in the 
rate of living donors.  
 
Pediatric patients receive mostly adult-sized kidneys from LD or deceased donors 
(DD). Living donors, in most cases recipients’ parents, account for one-third of all 
donors for pediatric RTx recipients in Finland. In recent years, the number of LD 
kidneys has increased up to 50%, which is similar to numbers in North America 
(NAPRTCS Annual Report 2014). In the Nordic countries, LD kidneys are the most 
common (60%) graft type among pediatric recipients (Jahnukainen et al. 2016). 
 
The benefits of LD kidneys comprise good donor quality, short cold-ischemia time 
and optimal timing of transplantation including pre-emptive transplantations 
(Jalanko et al. 2015). Additional advantages include elective surgery and alternative 
ABO incompatible (ABOi) transplantations. Pre-emptive RTx is a novel opportunity 
before initiating the dialysis if a living donor is available (Abramowicz et al. 2015). In 
Finland, the results of the first six pre-emptive transplantations have been 
promising.  
 
Transplantation techniques in children are similar to adults, and the operations are 
highly successful. Generally, the recipients are over 10 kg and the graft is placed 
extraperitoneally. Smaller (6–10 kg) infants are successfully transplanted with 
intraperitoneal engraftment (Chavers et al. 2007, Jalanko et al. 2015). 
Extraperitoneal placement allows easy access to ultrasound investigations and 
kidney graft biopsies needed for rejection diagnostics (Neipp et al. 2002). Vascular 
anastomosis requires appropriate matching of blood vessel sizes to enable 
Review of the literature 
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adequate perfusion of the adult-sized donor graft (Chavers et al. 2007, Salvatierra 
et al. 2006) (Figure 1).  
 
During transplantation, the kidney allograft may be exposed to several threats 
including prolonged cold-ischemia time, ischemia-reperfusion injury, and perfusion 
problems, all of which increase the risk for allograft injury (Galichon et al. 2013). 
Surgical complication occurs in 1 to 20% of the recipients (Rossi et al. 2016). The 
most common complication is lymphocele, which leads to perirenal fluid collection, 
and increases the risk for delayed graft function (Rossi et al. 2016, Ranghino et al. 
2015). Vascular thrombosis is another important cause of graft loss secondary to 
technical problems (Salvatierra et al. 2006). 
2.2.3 Histopathology  
Percutaneous core needle biopsies are essential diagnostic tools in clinical 
nephrology (Fiorentino et al. 2016). Kidney graft biopsies enable a safe and 
established method for monitoring the post-transplant course (Galichon et al. 2013, 
Birk 2012). The main indication for kidney graft biopsy is graft dysfunction, including 
increasing serum creatinine, decreasing GFR, proteinuria and hypertension 
regardless of histopathology.  
 
Histology reveals otherwise undetectable changes and is of invaluable importance 
when evaluating the degree and severity of the disorder, and to support diagnosis 
when the clinical manifestation is unclear. Vascular injury is characteristic of chronic 
changes that progress to fibrosis (Solez et al. 2007). Vasculopathy affects mainly 
the endothelium, which is the main target of immuniological and non-immunological 
mechanisms of injury (Bruneau et al. 2012). Common histopathological features in 
biopsies include interstitial fibrosis and tubular atrophy (IF/TA), glomerular 
abnormalities, and arteriolar hyalinosis (Alexander et al. 2007).  
 
CAI is a progressive process, which typically develops over years. The non-specific 
term ‘chronic rejection’ (which originally implied immunological factors) was 
misleadingly used for late scarring of the graft, and in 1991 it was replaced by the 
more specific expression ‘chronic allograft nephropathy’ (CAN). In turn, the term 
CAN became widely used as a non-specific description of fibrosis and graft 
dysfunction, despite the underlying disease processes. It was suggested that mixing 
many pathological processes with specific hallmark histopathology under the term 
CAN inhibited the accurate diagnosis and treatment of the real causes. Thus, CAN 
was replaced by a new definition, ‘chronic allograft injury’, which is histologically 
defined by IF/TA with no evidence of any specific etiology (Solez et al. 2007).  
 
The clinical manifestations of CAI include an increase in serum creatinine, 
proteinuria and hypertension, which appears as progressive renal dysfunction due 
to unrecognized causes. When specific causes are excluded, the non-specific term 
Review of the literature 
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CAI remains. In allograft biopsies, CAI is defined as IF/TA lesions, often in the 
presence of dynamic interplay between inflammation and fibrosis (Solez et al. 
2007). Tissue injury activates infiltrated leukocytes and inflammatory cells to 
produce cytokines and proinflammatory molecules. Moreover, activated fibroblasts 
produce collagens, which induces renal fibrosis. In fibrogenesis, several 
profibrogenic cytokines, such as transforming growth factor-β (TGF-β), bone 
morphogenetic protein (BMP), and hepatocyte growth factor (HGF) promote 
epithelial-to-mesenchymal transition (EMT), fibroblast activation and matrix 
deposition (Eddy 2014). IF/TA is defined as the excess accumulation of interstitial 
collagen and loss of normal tubular epithelial cell function in small, thin tubules 
(Zeisberg, Neilson 2010). Also, arterial lesions are prominent findings with intimal 
thickening and accumulation of foam cells, which leads to luminal narrowing. As 
larger arteries are generally affected while arterioles are spared, these chronic 
lesions may be undetectable on a kidney biopsy.  
 
Fibrosis is the final manifestation of the CAI regardless of the underlying etiology. 
The combination of IF/TA is a common and unspecific finding in patients with 
chronic allograft dysfunction. IF/TA develops over months to years without 
addressing the underlying disease processes, and is followed by a decline in graft 
function (Haas 2014). As a response to prolonged graft injury, deregulated repair 
process may result in excess deposition of extracellular matrix (ECM), fibrous scars 
and loss of graft function. Visual assessment of IF relies mainly on standard 
trichrome-staining (Moreso et al. 2001), although computer-assisted morphometric 
analyses of trichrome, Sirius Red and collagen immunohistochemistry may increase 
the accuracy (Farris et al. 2011). 
 
The etiology of CAI is multifactorial, and includes ischemia-reperfusion injury, acute 
rejection episodes, viral infections (cytomegalovirus, CMV; polyomavirus), chronic 
immunoactivity, and nephrotoxicity of calcineurin inhibitors (CNIs). Also, the 
diseases of the donor influence the progress of transplant destruction (Chapman et 
al. 2005), and lesions may have immunological or non-immunological origin (Table 
2), although the roles of different mechanisms of injury are unclear. Thus, it is 
important to distinguish the underlying pathologic mechanisms in order to prescribe 
appropriate treatment (Halloran 2002, Galichon et al. 2013). Histopathologic lesions 
of CAI occur late and thus do not differentiate the underlying cause. 
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Table 2. Risk factors that influence kidney graft survival 
Non-immunological 
 Donor-related factors 
  Donor age and tissue quality 
  Brain death-related stress 
  Preservation and implantation injury 
 Recipient related-factors 
  Post-transplant stress factors, i.e., BKPyV and CMV infections 
  Metabolic syndrome 
  CNI toxicity 
Immune-mediated injury 
 Rejections 
  TCMR Severe rejections with endothelial injury 
  ABMR Might occur late due to non-compliance 
 HLA mismatches 
 Donor-specific HLA antibodies  
 Under-immunosuppression/non-compliance 
 Sensitization to foreign HLA  
  Pre-RTx Previous blood transfusions, pregnancies or transplantation 
  Post-RTx DSA 
BKPyV, BK polyomavirus; CMV, cytomegalovirus; CNI, calcineurin inhibitor; TCMR, T-cell mediated 
rejection; ABMR, antibody-mediated rejection; HLA, human leucocyte antigen; DSA, Donor-specific 
HLA antibodies; RTx, renal transplantation. Adapted from (Halloran 2002, Galichon et al. 2013). 
 
 
The presence of abnormalities in implantation biopsies varies in up to 40%, 
depending on donor age and quality and kidney recovery after transplantation 
(Lehtonen et al. 2001). Irreversible allograft fibrosis is present in over half of the 
post-transplant biopsies by 10 years and associates with a decline in graft function 
(Nankivell et al. 2003). Observational studies have demonstrated that persistent 
inflammation, especially in the area of fibrosis, is harmful and associates with poor 
graft function (Heilman et al. 2010, Mengel et al. 2007, Cosio et al. 2005). However, 
the graft function is not a sensitive marker of the underlying severity of graft 
pathology (Legendre et al. 1998).  
 
Semiquantitative histological evaluation of allograft biopsies follows standardized 
criteria. The Banff classification and its most recent revision, Banff’13 (Haas et al. 
2014), are used worldwide for biopsy interpretation (Solez et al. 2007). Three main 
categories are divided into subcategories that comprise specific diagnostic criteria 
(Table 3). Other scoring systems, e.g. chronic allograft damage index (CADI) 
(Isoniemi et al. 1994) are also used to describe detailed histological findings and to 
further associate findings with graft outcomes (Yilmaz et al. 2003). Diagnosis of the 
graft biopsy is mainly based on light microscopy and immunohistochemistry.  
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Table 3. Banff classification  
Diagnostic categories for kidney allograft biopsies according to Banff1 classification 
1 Normal  
2 Antibody-mediated rejection (ABMR) 
  Acute/active ABMR 
  Chronic/active ABMR 
  C4d positivity without evidence of rejection 
3 Borderline changes 
  Mild tubulitis (t0-t1), mild interstitial inflammation 
4 T-cell-mediated rejection (TCMR) 
  Acute: IA, IB, IIA, IIB, III 
  Chronic/active 
5 Interstitial fibrosis and tubular atrophy 
  Mild, moderate, severe 
6 Other  
  Changes not thought to be due to rejection 
  i.e., CNI toxicity, chronic hypertension or obstruction, bacterial pyelonephritis, 
viral infection. May coincide with categories 2–5. 
CNI, calcineurin inhibitor. 1 Banff '97 criteria, revised in '05 and '13. Modified from detailed Banff criteria 
(Racusen et al. 1999, Solez et al. 2007, Haas et al. 2014).  
2.2.4 Biomarkers of allograft injury 
Biomarkers are objective indicators that can be classified as prognostic, predictive 
or surrogate end points (Lo et al. 2014). In kidney transplantation, many established 
biomarkers are in clinical use, i.e., serum creatinine and human leukocyte antigen 
(HLA) match between donor and recipient (Roedder et al. 2011). However, 
identification of novel biomarkers that could replace invasive biopsies and 
accurately reflect the allograft function is important.  
 
Renal biopsy visualizes the current histopathology, but provides limited data on   
possible mechanisms of allograft injury (Henderson et al. 2011). 
Immunohistochemistry is a sensitive method used to detect structural mesenchymal 
markers, especially when biomarkers are expressed de novo (Galichon, Hertig 
2011).  
 
Serum biomarkers, which may improve the ability to diagnose specific pathologic 
mechanisms of CAI or predict outcomes, are presented in Table 4. Although the 
urinary biomarker candidates for acute kidney injury and acute rejection are 
numerous (Lo et al. 2014, Sigdel et al. 2016, Westhoff et al. 2016), none of the 
quantitative biomarkers of CAI has yet been validated for clinical use. Recently, 
varieties of non-invasive biomarkers have been studied as potential surrogates for 
CAI (Stegall et al. 2015, Stegall, Borrows 2015).  
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Table 4. Biomarkers involved in renal fibrogenesis or outcome 
Indication/marker Description of positivity/outcome EMT Ref. 
Markers of epithelial-to-mesenchymal transition (EMT)  
Cytoskeletal markers   
 Vimentin Intermediate filament, mesenchymal cells + (Hertig et al. 2008) 
 α-SMA Interstitial myofibroblasts + (Galichon, Hertig 2011) 
 β-catenin Translocation in the cytoplasm + (Hertig et al. 2006) 
 FSP1; S100A4 Tubular epithelial cell marker + (Vitalone et al. 2008) 
 Cytokeratin Tubular epithelial cell marker - (Vongwiwatana et al. 2005) 
Extracellular matrix (ECM) proteins  
 Collagens ECM and basement membrane constituents 
+ (Rastaldi et al. 2002) 
 HSP47 Marker of collagen production + (Rastaldi et al. 2002) 
Cell-surface proteins  
 N-cadherin Mesenchymal cells + (Zeisberg, Neilson 2009) 
 E-cadherin Tubular epithelial cell marker - (Vitalone et al. 2008) 
Inhibitors of EMT   
 HGF Anti-fibrotic molecule, counteracts TGFβ - (Yang et al. 2005) 
 BMP-7 Anti-fibrotic molecule, counteracts TGFβ - (Zeisberg et al. 2003) 
Markers of endothelial-to-mesenchymal transition  
 Fascin 1 Actin-bundling protein in endothelial cells  (Xu-Dubois et al. 2016) 
Markers associated with post-transplant outcome 
KIM1 Marker of general renal injury  (Malyszko et al. 2010) 
(van Timmeren et al. 2007) 
Growth factors   
 TGF-β Profibrotic factor, initiate/maintain EMT + (Zeisberg, Neilson 2009) 
 CTGF Profibrotic molecule + 
(Xu-Dubois et al. 2013) 
 FGF-23   
(Seifert et al. 2016) 
Proteases   
 MMPs   
(Catania et al. 2007) 
Gene expression signatures (microRNA, microarray) in renal biopsies  (Baron et al. 2015) 
 Correlated with AR, ABMR, IFTA, and 
GFR 
 (Stegall, Borrows 2015) 
 (Loupy et al. 2014) 
 (Halloran et al. 2013) 
   (Anglicheau et al. 2012) 
Immune monitoring  
 
HLA antibodies DSA with C1q and C3d binding 
 (Fichtner et al. 2016) 
 (Comoli et al. 2016) 
  (Lefaucheur et al. 2016) 
 (Loupy et al. 2013) 
 Non-HLA antibodies MICA antibodies  (Opelz, Collaborative Transplant Study 2005) 
EMT, epithelial-to-mesenchymal transition; α-SMA, alpha-smooth muscle actin; FSP1, fibroblast-
specific protein-1; ECM, extracellular matrix; HSP47, heat shock protein 47; HGF, hepatocyte growth 
factor; BMP-7, bone morphogenetic protein 7; KIM1, kidney injury molecule 1; TGF- β, transforming 
growth factor beta; CTGF, connective tissue growth factor; FGF, fibroblast growth factor; MMP, matrix 
metalloproteinase; DSA, donor-specific HLA antibodies; MICA, major-histocompatibility-complex class 
I–related chain A. 
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The requirements for novel non-invasive, reliable and predictive biomarkers are 
high. The optimal time point for the measurement, appropriate thresholds and the 
features to reflect progression beyond other clinical conditions warrant additional 
clinical considerations. The development of novel candidate biomarkers, 
transcriptomics and proteomics, requires a variety of platforms (i.e., microarray, 
quantitative real-time PCR, and microRNAs) to assess their performance (Ying, 
Sarwal 2009, Anglicheau, Suthanthiran 2008). Validation of such markers would 
bring clear clinical value in the form of individualized therapy (Asadullah et al. 2015). 
This might decrease the rate of adverse effects, reduce costs and improve the long-
term outcome (Ho et al. 2012).  
 
 
2.3 Transplantation immunology and immunosuppression 
The immune system protects us from foreign pathogens and microbes. In the case 
of transplantation, the recipient immune system reacts against the foreign allograft 
and gradually rejects it, if the immune response cannot be circumvented with 
adequate immunosuppressive medication.  
2.3.1 Human leukocyte antigen system 
HLA molecules are polymorphic proteins and important targets for immune 
recognition in organ transplantation (Figure 3). To date, the known HLA 
polymorphism is extremely high and identifies over 10,000 allele sequences, double 
the number in the early 2010s (Thorsby 2009, Terasaki 2013). Polymorphism 
hampers HLA matching and predisposes to rejections, leading to a need for lifelong 
immunosuppression. In addition, alloreactivity increases with age, as circulating T- 
and B-cell subtypes and immunologic features develop from birth to adulthood, 
although children with ESRD may have suboptimal immune responses (Hartel et al. 
2005, Dharnidharka et al. 2014).  
 
HLA class I molecules are present in the cell surface of almost all nucleated cells, 
whereas HLA class II molecules are only found on the surface of antigen-presenting 
cells (APCs) such as dendritic cells, macrophages, B cells, monocytes and 
endothelial cells. APCs present HLA molecules with bound peptides for two types of 
cells. HLA class I molecule binds foreign proteins degraded inside the cell 
(endogenous pathway) and activates CD8 T cells (cytotoxic lymphocytes). Foreign 
protein degraded outside the cell (exogenous pathway) binds to HLA class II 
molecules, which in turn activates CD4 T lymphocytes (T helper cells) (Candon S, 
Marguiles DH 2004) (Figure 3). 
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2.3.2 Histocompatibility 
Minimization of immunological differences between donor and recipient is crucial for 
successful kidney transplantation. Tissue typing prior to RTx includes four 
components: HLA and ABO matching, screening for HLA antibodies (HLAab), and 
cross matching.  
 
ABO matching compares blood types of the kidney recipient and donor. Blood 
groups A, B and O have traditionally constructed the ABO barrier, which allows the 
transplantation of a kidney allograft with compatible antigens only to avoid rejection 
by anti-ABO antibodies. In ABO-incompatible (ABOi) transplantation, the recipient 
has antibodies against graft AB-antigens prior to preoperative management. In 
young children, the immature immune system allows organ transplantations across 
traditional ABO barriers. In the past 15 years, more than 3,000 ABOi living donor 
kidney transplantations have been reported worldwide. Long-term graft survival is 
comparable to ABO-matched LD kidneys (Zschiedrich et al. 2016), and ABOi 
transplantations are suggested to partly resolve the increasing need for new donors.  
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Figure 3 In humans, the major histocompatibility complex (MHC) is termed the human leukocyte 
antigen (HLA) system. This highly polymorphic gene family is located on the short arm of 
chromosome 6, and divided into three main regions encoding different cell surface 
protein molecules, antigens. MHC class I genes encode HLA-A, HLA-B, HLA-C 
molecules while MHC class II genes encode HLA-DR, HLA-DQ, HLA-DP molecules. The 
MCH class III genes encode important molecules for inflammation, such as components 
of complement (Candon S, Marguiles DH 2004).  
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HLA typing compares tissue types of the recipient and donor. HLA-A, -B, and -DR 
antigens have an important role in transplantation, and are matched to reduce the 
risk of post-transplant rejection, although other antigens may also trigger rejection 
episodes. HLA-DR is the most immunogenic locus, followed by the HLA-B and HLA-
A loci. This explains the importance of HLA-DR matching, although polymorphism 
complicates the matching of unrelated donors and kidney recipients (Candon S, 
Marguiles DH 2004). 
 
The panel reactive antibody (PRA) test with cytotoxic panel identifies HLA reactivity 
before transplantation. It determines how likely the patient is to have antibodies 
against the donor organ, and is used as a risk assessment tool. Immunization 
against donor HLA antigens is possible prior to transplantation as a result of blood 
transfusions, pregnancy, or previous transplantation. Sensitization to HLAab often 
delays the finding of an acceptable donor, and sensitized recipients are at increased 
risk of severe rejection episodes if the antibody response is directed against donor-
antigens or a cross-reactive polyclonal group.  
 
Detection of HLab is conventionally assessed by complement-dependent cytotoxic 
testing (CDC), although it lacks sensitivity in detecting clinically significant HLAabs. 
In turn, Luminex assay is a highly sensitive and specific method recently used in 
organ allocation and risk assessment by measuring pretransplant and 
posttransplant HLAab levels (Konvalinka, Tinckam 2015) (Table 5).  
 
Table 5. Technological aspects of Luminex 
 Technological advantages Technological limitations 
Qualitative Precise identification of all antibody 
specificities  
False positivity due to antibodies to 
denatured HLA 
Comprehensive  Detection of all common alleles Occasional background requires repeat 
testing and absorption protocols 
Semiquantitative Determination of high, intermediate, 
and low levels of ab 
Variable HLA protein density in beads, 
risk for false-negative or misleading 
low assessments  
Sensitive Detects weak antibodies  
Rapid Real-time ab monitoring, assists 
diagnosis of ABMR 
Lot-specific variation 
Non-HLA-specific 
antibodies  
Detection of MICA  
Complement / non-
complement fixing 
Differentiation of C4d and C1q Reagents not standardized 
HLA, human leukocyte antigen; ABMR, antibody-mediated rejection; MICA, major-histocompatibility-
complex class I-related chain A. Modified from (Tait et al. 2013). 
 
 
Crossmatch testing is performed at the time of transplantation, and is designed to 
prevent hyperacute and acute rejections. Recipient serum is tested with 
lymphocytes from the donor. A positive crossmatch usually indicates the presence 
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of preformed donor-specific HLA antibodies (DSA), which results in rejection, and 
thus the transplantation is not performed. 
 
Interpretation of solid-phase assays requires understanding of the challenges of the 
methodology to define the clinically relevant threshold for mean fluorescence 
intensity (MFI) positivity and to consider quantitative limitations (Figure 4). Serial 
testing of antibody levels over time is preferable to a single-antibody testing. The 
interpretation of results is affected by many variables, such as adherence to 
immunosuppression, latency period, and change in antibody levels due to memory 
B cell responses and dynamic changes in DSA MFI levels (Konvalinka, Tinckam 
2015). 
 
 
Figure 4 An individual example of a common solid-phase assay result (Fusion 3.0 software). MFI 
appears on the y-axis, and each bar indicates a single bead of the HLA allele.  
Post-transplant monitoring of HLAab assesses the risk for impaired allograft 
survival. DSAs are a significant risk factor for humoral rejection, although many 
grafts function well despite the presence of DSA. The appearance of DSA is 
diagnostic in humoral rejection with or without C4d deposition in peritubular 
capillaries (Haas et al. 2014). Prospective monitoring of DSA after the first post-
transplant year is costly, with limited benefits, and seems mostly valuable in 
healthier patients at a higher risk for de novo DSA (dnDSA) (Kiberd et al. 2016). 
2.3.3 Immune response 
The immune system can be divided into two protection barriers, innate and adaptive 
immunity against pathogens.  
 
Innate immunity is responsible for the first line response against foreign tissue, 
pathogens and tissue injury. In transplantation, ischemia-reperfusion injury activates 
the innate immunity response, which comprises complement activation, leukocyte 
recruitment, natural killer (NK) cells, and acute phase proteins. It occurs rapidly, 
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without memory. Acute infection and inflammatory cells increase cellular damage, 
which may provoke acute rejection early after transplantation. Innate immunity helps 
to activate the more specific adaptive immune response (Heeger 2003).  
 
In adaptive immune response, recipient’s T lymphocytes recognize foreign 
alloantigens, leading to alloantigen-specific immunity (Chalermskulrat et al. 2004). 
Adaptive immunity is slow, antigen-specific and poorly effective without innate 
immunity, but results in memory. 
 
After transplantation, recipient’s T-lymphocytes recognize allogeneic graft tissue as 
a foreign threat (T-cell allorecognition). HLA antigens may induce cellular (T cell-
mediated) immunity or humoral (antibody-mediated) immunity. Cellular immunity to 
HLA antigens is further divided into direct and indirect allorecognition pathway.  
 
In direct recognition, recipient’s T cells interact with incompatible HLA antigens on 
the surface of donor APC cells. Self-restricted T cells are specialized to recognize 
these foreign allogenic HLA/peptide complexes (Heeger 2003). This leads to 
infiltration of recipient T-cell into the graft as a cellular immune response to initiate 
tissue injury. In general, HLA class I molecules activate CD8+ cytotoxic T cells, 
while HLA class II antigens activate CD4+ helper and effector T cells. Direct 
allorecognition early after RTx leads to severe immediate immune response, 
whereas the indirect pathway occurs over time (Figure 4). 
 
In indirect recognition pathway, recipient’s APCs take up donor-specific antigens 
and present these to the recipient’s own T cells. Acute cellular rejection is an 
activation of alloreactive T cells and APCs. Different cell types are present, such as 
proinflammatory leukocytes, CD4+ helper cells, CD8+ cytotoxic T cells and 
antibody-forming B cells. The kidney graft is a continuous resource for donor 
antigens, which may lead to development of chronic allograft injury over time.  
 
In humoral immunity, activated B cells mature and differentiate into alloantibody-
producing plasma cells and memory B cells. Most alloantibodies react against class 
I and/or class II HLA antigens that are distinct from the recipient, but also non-HLA 
antibodies, such as anti-endothelial cell antibodies, have been regarded as an 
important risk factor for chronic rejection and graft failure (Delville et al. 2016). In 
fact, the rejection process involves the entire immunologic response system in 
addition to T cell and B cell cascades.  
 
Immunological tolerance in transplantation biology would enable to silencing the 
immune response against the allogeneic graft tissue while immunity to infections 
and malignancy remained intact. 
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Figure 5 Allorecognition, direct and indirect pathway. T-cell activation depends on the recognition 
of the HLA and foreign peptide complex. As the HLA/peptide complex engages the T-
cell receptor (TCR), additional co-stimulatory and adhesion molecules are activated to 
provide the proper combination of signals. If T cells recognize this complex to self-
antigens of the recipient, T cells remain inactive, whereas recognition to non-self 
antigens of the donor leads to T-cell activation, proliferation and rejection. Modified from 
(Fine et al. 2007). 
2.3.4 Immunosuppression 
Successful immunosuppression comprises a continuous balance between 
rejections and an acceptable number of side effects (Srinivas, Meier-Kriesche 
2008). The early post-transplant period with intense immunosuppression is 
challenging, with individual variation in medications and differences across 
transplant programs (Axelrod et al. 2016).  
 
The importance of immunosuppression is more pronounced early after RTx, as 
most acute rejections occur during the first 6 months post-Rtx (Nankivell et al. 
2003). At the maintenance phase, graft adaptation reduces the need for rejection 
prophylaxis and doses are gradually reduced. Thus, the risk of rejection and the 
level of immunosuppression decrease with time.  
 
Most immunosuppressive regiments act against the T lymphocytes. T cells require 
three signals to be activated, and all these are potential interaction sites for 
immunosuppressive drugs (Halloran 2004) (Figure 5). Medications interrupt 
lymphocyte proliferation, interfere with lymphocyte differentiation and cell co-
stimulation, deplete cells and induce tolerance.  
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Figure 6 Targets of immunosuppression. Modified from Halloran 2004. 
Multidrug combination therapy provides synergistic efficacy and allows the use of 
reduced doses to avoid drug-related and dose-dependent side effects. Initial 
immunosuppression is tailored to the needs of the recipient in order to ensure 
efficacy and tolerability and to control the appearance of side effects (Augustine, 
Hricik 2007). The diversity of immunosuppressants has led to wide variation in 
protocols, and the medication used partly depends on center-level practice rather 
than on individual needs (Axelrod et al. 2016). 
 
Calcineurin inhibitors (CNIs) have been the basis of modern immunosuppression 
over the past two decades. CNIs, cyclosporine A (CsA) and tacrolimus are effective 
immunosuppressants that induce good survival rates and graft function, although 
both are nephrotoxic (Srinivas, Meier-Kriesche 2008). They selectively suppress the 
activation and production of T cells and inhibit the release of IL-2 and other 
cytokines.  
 
Cyclosporine A prevents transcription of the interleukin-2 gene, which, in turn 
affects cytotoxic T-cell precursors and inhibit the activation of T lymphocytes. As the 
therapeutic window between efficacy and toxicity is narrow, negative side effects 
are common and therapeutic drug monitoring mandatory (Tredger et al. 2006). CsA 
metabolism, via cytochrome P450 isoenzyme 3A4, causes individual variability in 
pharmacokinetics and significant drug interactions, and in general, children require 
higher doses of CsA than adults (Tredger et al. 2006).  
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Tacrolimus is the other main immunosuppressant, which has similar graft and 
patient survival outcomes as CsA. Tacrolimus might be more potent in rejection 
prophylaxis and thus be more favorable for renal function. Despite the reduction in 
acute rejection rate, the use of tacrolimus does not significantly improve the overall 
graft survival. Currently, no CNI is superior to another, and withdrawal or 
replacement of CNIs due to increased nephrotoxicity or early graft loss is no longer 
considered (Stegall et al. 2015).  
 
Antimetabolites inhibit the synthesis of nucleic acids. Mycophenolates 
(mycophenolate mofetil, MMF and enterocoated mycophenolate sodium) inhibit the 
differentiation and proliferation of lymphocytes. Mycophenolates are selective for 
lymphocytes and provide specific immunosuppression with an acceptable side 
effect profile (gastrointestinal, CMV, bone marrow suppression). The use of MMF 
with prednisolone and CNI allows CNI sparing (Halloran 2004). MMF is commonly 
combined with tacrolimus. Most importantly, the combined use reduces the rejection 
rate, and MMF is not nephrotoxic and lacks increased cardiovascular risks (Srinivas 
et al. 2005). 
 
Azathioprine is a purine analog, which unselectively inhibits DNA synthesis and the 
proliferation of lymphocytes (Tredger et al. 2006). Azathioprine was the first 
immunosuppressant used worldwide until the introduction of CsA. Currently, Aza 
has mostly been replaced by MMF in adults.  
 
Glucocorticoids (corticosteroids) have remained a part of standard 
immunosuppressive therapy over the past 50 years of practice.  Steroids bind to the 
glucocorticoid receptor and down-regulate inflammatory cytokines. This unspecific 
anti-inflammatory effect has many potential effects on the immune system, 
simultaneously with a large number of adverse effects. To reduce steroid-
associated side effects, some centers use steroid withdrawal or steroid-free 
protocols. Steroid withdrawal is possible with careful planning, although the benefits 
are debated and depend on timing and co-medications (Grenda 2013, Webb et al. 
2015). 
 
Inhibitors of the mammalian target of rapamycin (mTOR), sirolimus and everolimus, 
inhibit the proliferation of cytokine-dependent T lymphocytes, mesenchymal cells 
and tumor cells. As mTOR inhibitors have a highly synergistic effect with CNI, they 
allow a reduction in CNI levels without any impact on efficacy. Combination 
immunosuppression with sirolimus and MMF improves long-term graft function 
compared to the combination of CNI and MMF (Weir et al. 2016).  
 
Induction therapy is prophylactic, perioperatively administered immunosuppression. 
It is effective in reducing initial rejections. Induction therapy includes polyclonal and 
monoclonal antibodies against T cells, such as anti-thymocyte globulin, which 
results in depletion of T cells. Basiliximab is a monoclonal interleukin-2 receptor 
antibody used in induction at the study center. Careful risk-benefit assessment is 
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necessary as induction therapy increases the risk for opportunistic infections and 
malignancy.  
 
Rituximab is a monoclonal anti-CD20 antibody, which depletes peripheral B cells 
and is used in desensitization protocols, prophylaxis and treatment of humoral 
rejections, and in treatment of post-transplant lymphoproliferative disorder (PTLD). 
Betalacept, in turn, blocks co-stimulation and is used as a part of CNI-free regimen. 
Desensitization protocols include the use of plasmapheresis, immunoabsorption, 
intravenous immunoglobulins (IVIG) and rituximab to remove circulating HLA 
antibodies.   
 
The side effects of immunosuppression are in general non-specific, and comprising 
increased risk for malignancy and opportunistic infections. Infections are the main 
problem during the first year post-RTx, whereas malignancy is important in the long-
term. Each immunosuppressant has additional, specific, often dose-dependent side 
effects, as listed in Table 6. CNIs are nephrotoxic, which may lead to functional or 
structural damage, which may be reversible or irreversible, respectively. Functional 
arteriolar vasoconstriction causes hypoperfusion of the kidney graft, which leads to 
a decreased GFR. This phenomenon is mostly reversible and dose-dependent, and 
induced by high CNI doses at the early post-RTx phase (Naesens et al. 2009). 
Striped fibrosis is a characteristic but non-specific histologic feature for chronic CNI 
toxicity. Vacuolar changes, hyaline deposits and thrombotic microangiopathy may 
indicate CNI nephrotoxicity, although histological characteristics are not specific for 
CNI toxicity (Mengel et al. 2011).  
 
Table 6. Side effects of immunosuppressive medication 
Side effects CsA Tacro AZA MMF Steroids 
Nephrotoxicity +++ +++ - - - 
Hypertension +++ ++ - - +++ 
Hypercholesterolemia ++ + - - ++ 
Diabetes + +++ - - ++ 
Osteoporosis + + - - +++ 
Neurotoxicity ++ +++ - - + 
Myelosuppression - - + + - 
Gastrointestinal + + + +++ - 
Hepatotoxicity + + + - - 
Cosmetic side effects + - - - + 
Risk of PyVAN + ++ - + - 
CsA, cyclosporine A; Tacro, tacrolimus; AZA, azathioprine; MMF, mycophenolate; PyVAN, 
polyomavirus-associated nephropathy (Webster et al. 2005, Halloran 2004). 
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2.4 Complications and long-term outcome 
Post-transplant complications can be classified into graft-related (i.e., delayed graft 
function or acute tubular necrosis), technical (i.e., vascular thrombosis) or 
anatomical (i.e., obstruction). However, the immune response of the recipient 
causes the most problematic complications, such as rejections and secondary 
effects of immunosuppression, i.e., infections, malignancy and growth problems 
(Table 7).  
 
Table 7. Post-transplant complications in relation to time after RTx in children 
Time after RTx Complication 
Immediate, 0-1 week 
  Delayed graft function (oliguria, need for dialysis) 
  Acute tubular necrosis 
  Vascular thrombosis 
  Urologic complication (leak or obstruction) 
Early, 1-12 weeks  
  Acute rejection 
  CNI toxicity 
  Urinary obstruction 
  Hypovolemia 
  Infections 
  Recurrence of the primary disease 
Late chronic, years 
  Cardiovascular and metabolic complications 
  Hypertension 
  Anemia 
  Low-grade inflammation 
  Growth and skeletal complications 
  Psychosocial complications, i.e., non-compliance 
  Malignancies (PTLD) 
RTx, renal transplantation; CNI, calcineurin inhibitor; PTLD, post-transplant lymphoproliferative 
disease. 
2.4.1 Rejection-related graft injury 
Most acute rejection episodes occur early during the first three months post-RTx, 
and are characterized by an increase in serum creatinine and specified findings on 
core needle biopsy (Nankivell et al. 2003). After that, late acute rejections frequently 
associate with under-immunosuppression or non-compliance. Subclinical rejection 
corresponds to histology of acute rejection without graft dysfunction. Acute rejection 
episodes are treated with high doses of intravenous methylprednisolone pulses. 
Conversion from CsA to tacrolimus, the use of antibody removal/neutralization by 
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plasmapheresis, anti B-cell therapies (Rituximab) or T-cell depleting agents (anti-
lymphocyte globulin) may add efficacy. In the presence of CNI nephrotoxicity, 
reduction of CNI regimen may inhibit the histopathologic progression.   
 
In T cell-mediated rejection (TCMR), T lymphocytes infiltrate into the graft. 
Accumulation of T cells in the peritubular capillaries, tubule walls and interstitium is 
called tubulointerstitial rejection. This is the most common form of acute cellular 
rejection. Arterial cell-mediated rejection is characterized by accumulation of 
mononuclear leukocytes in the arterial walls, and these ominous lesions are less 
responsive to steroids. Acute transplant glomerulopathy is a rare and severe form of 
cellular rejection, detected as severe glomerular inflammation and cellular damage, 
which may exist without tubulo-interstitial rejection. No C4d positivity in tissue or 
DSA in blood is present. Recent studies suggest that TCMR shares common 
features with ABMR, and novel molecular methods are investigated to elucidate the 
more detailed pathogenesis of different types of graft injury (Reeve et al. 2016). 
 
Antibody-mediated rejection (ABMR) response may appear as acute rejection within 
weeks to months or as chronic rejection within years. Variation in the time course of 
the antibody response is significant, making the screening/monitoring of antibodies 
demanding. Monitoring of HLA antibodies is necessary as circulating DSA may 
otherwise cause immediate hyperacute rejection and constitute a significant risk 
factor for transplant glomerulopathy and graft loss (Cardarelli et al. 2005). Biopsy is 
recommended in the presence of post-transplant DSA and the subsequent 
treatment is mainly based on the biopsy results (Tait et al. 2013). 
 
Endothelial cells in the graft are exposed to recipient’s serum and are a common 
site for antibody-initiated injury. In ABMR, donor-specific antibodies react against 
endothelial antigens. The key mechanism for the allograft injury and inflammation 
during ABMR includes the complement fixation by DSA and thus activation of the 
complement cascade (Thomas et al. 2015). It may appear as hyperacute, 
acute/active or chronic/active ABMR. Several subtypes of ABMR have recently 
been investigated (Halloran et al. 2016). 
 
In acute/active ABMR, the main lesions are microvascular and may affect either, 
glomerular, arterial, or peritubular capillaries.  Diagnosis is possible even in the 
absence of C4d complement component, as the most recent Banff classification 
(Banff 2013) includes C4d-negative ABMR (Haas et al. 2014). Previously, 
immunohistopathological evidence, i.e., C4d positivity, was required for the 
diagnosis of ABMR (Solez et al. 2007).  
 
Chronic/active ABMR comprises chronic tissue injury manifesting as transplant 
glomerulopathy and arteriopathy, multilayering of peritubular capillaries, and 
evidence of microvascular inflammation and DSAs (Haas et al. 2014). 
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2.4.2 Infections 
Post-transplant infections are a major post-transplant complication (Dharnidharka et 
al. 2014). Infections are the main cause of admission to the hospital after RTx in 
children, and account for 36% of the deaths in European pediatric RTx patients 
(Chesnaye et al. 2014), as viruses infect people early in life. Young pediatric 
recipients are at a higher risk of viral transmission from a seropositive adult donor 
organ with a latent virus, and thus at a higher risk of severe disease as compared to 
adults (Dharnidharka et al. 2014, Dharnidharka et al. 2009).  
 
Early infections are usually caused by bacteria or yeast and related to invasive 
procedures affecting wounds and transplant (Table 8). The later period is 
characterized by the onset of opportunistic infections, which may be reactivated or 
transmitted from the donated organ due to intense immunosuppressive therapy. 
Epstein-Barr virus (EBV)-associated PTLD is a serious complication of 
immunosuppression, which accounts for about 95% of the malignancies in pediatric 
patients. Unlike in adults, non-PTLD malignancies are rare in pediatric RTx 
recipients.  
 
 
Table 8. Infectious post-transplant complications among pediatric RTx recipients 
Pathogen Complication 
Time of 
infection, 
months 
post-RTx 
Frequency of 
post-RTx 
hospitalization* 
At 1-5 mo At 3 yrs 
Total infections   51.4% 21.1% 
Bacterial (Staph. Aureus/Epidermidis, E.Coli) UTI, septicemia 0-1 13.1% 5.3% 
Viral   1-6 13.7% 4.7% 
 Cytomegalovirus (CMV) CMV infection    
 Epstein-Barr virus (EBV) PTLD > 6   
 Polyomaviruses, BK and JC  PyVAN > 6   
Fungal (Candida, Aspergillus) UTI, oral/skin 0-1 1.0% 0.2% 
*According to NAPRTCS 2014 Annual report, deceased donor recipients. UTI, urinary tract infection; 
PyVAN, polyomavirus-associated nephropathy, PTLD, post-transplant lymphoproliferative disorder. 
 
 
Although CMV infections at 6 months post-RTx have increased from 10% to 30%, 
CMV rarely causes a life-threating disease due to improved diagnostic tools, 
gansiclovir prophylaxis or pre-emptive treatment (Helanterä et al. 2010, Helanterä et 
al. 2014). Serial PCR monitoring for viral replication enhances early detection and 
interventions (Al Khasawneh et al. 2013). CMV prophylaxis is associated with 
preserved graft function (Hocker et al. 2016) and is recommended for a minimum of 
3 months, or 6 months for high-risk (donor positive/recipient negative, D+/R-) 
recipients.  
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BK and JC polyomaviruses 
 
BK polyomavirus (BKPyV) has emerged as an important post-transplant pathogen 
in kidney transplant recipients. The increase in the incidence of BKPyV infections 
associates with the combined use of tacrolimus and mycophenolate (Hirsch et al. 
2013). Among recipients using these agents, approximately 3–5% will develop 
BKPyV infection in the graft, and BKPyV is the main cause of polyomavirus-
associated nephropathy (PyVAN).  
 
The first sign of active virus replication is BK viruria, which precedes BK viremia and 
allows early prediction of PyVAN (Babel et al. 2009). Viral loads of > 10,000 
copies/mL in blood and > 10 million copies/mL in urine are determined as clinically 
relevant and predictive for the pathology of PyVAN.  
 
In RTx recipients, intense immunosuppression may induce reactivation of the latent 
BKPyV, which converts subclinical replication to viremia and viruria in 21–26% and 
33–63% of the pediatric recipients, respectively (Haysom et al. 2004, Zarauza 
Santovena et al. 2015). BKPyVAN affects up to 10% of RTx patients and leads to 
allograft loss in 10–80%  (Schaub et al. 2010). In pediatric patients, the 
corresponding prevalences are around 5% and 24% (Smith et al. 2007). Donor-
derived de novo BKPyV infections associate with serostatus discordance (D+/R-) 
(Sood et al. 2013, Verghese et al. 2015, Schwarz et al. 2015). 
 
PyVAN is diagnosed by histological evaluation of the kidney graft biopsy and 
immunohistochemistry using anti-simian virus 40 (SV40) antibodies. BKPyV 
replication causes viral cytopathy, increasing inflammatory infiltrates and IF/TA 
changes, which are difficult to distinguish from the morphology of acute rejection. 
Histological lesions are multifocal and randomly distributed; more than one-third of 
the results may thus be false negative due to uninvolved parenchyma at the biopsy 
sampling area. This hampers the differential diagnosis from acute cellular rejection, 
which has similar clinical symptoms but requires radically different therapy. In fact, 
studies of HLA-DR (MHC class II) expression on tubular epithelial cells and 
complement C4d deposits may provide help to distinguish BKPyVAN from rejection, 
as patients with BKPyVAN lack these features. 
 
Treatment of BKPyVAN relies on reduction of immunosuppression, and the 
effectiveness of antiviral drug therapy is in doubt. Cidofovir and leflunomide have 
been used, although not validated, in adults or children (Dharnidharka et al. 2011). 
Virus-neutralizing antibodies show potency as a new anti-BKPyV therapy, although 
evidence is still lacking from in vitro studies on how these immune globulins would 
perform in clinical use (Randhawa et al. 2015, Pastrana et al. 2012). 
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2.4.3 Inflammation 
Persistent inflammation is a common complication in patients with ESRD before 
renal RTx (Carrero, Stenvinkel 2009, Miyamoto et al. 2011). Transplantation 
diminishes inflammation and thus decreases the risk of cardiovascular 
complications and mortality. However, transplant recipients have an altered immune 
system, and low-grade inflammation increases the risk for graft-related 
complications and impaired long-term survival (Abedini et al. 2009, Cottone et al. 
2007).  
 
Inflammatory stimulus, such as kidney tissue injury, activates the rapid cascade of 
increasing cytokines interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and C-
reactive protein (CRP). Upstream in the inflammatory cascade, IL-6 is the main 
inducer of the hepatic production of CRP (Gabay 2006) (Figure 7). IL-6 has an 
important role in the recruitment of monocytes and in activating the cellular immune 
response. In turn, any inflammatory state such as uremia or atherosclerosis may 
also hamper graft function (van Ree et al. 2007) 
 
Post-transplant CRP levels were studied already a decade ago in the presence of 
allograft nephropathy (Sezer et al. 2004). Currently, the development of a sensitive 
CRP assay enables more precise measurements to detect the harmful effect of 
persistent low-grade inflammation on patient survival (Dahle et al. 2011). 
Inflammation markers IL-6 and high-sensitivity C-reactive protein (hsCRP) are 
independently predictive of cardiovascular events and mortality in renal transplant 
recipients (Abedini et al. 2009). 
 
 
 
Figure 7 Inflammatory cascade and the pattern of anemia of inflammation. IL-1, interleukin-1; 
TNF-α, tumor necrosis factor alpha; IL-6, interleukin-6; CRP, C-reactive protein. 
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2.4.4 Anemia 
Renal transplant recipients face the risk of developing hematologic abnormalities 
and post-transplant anemia (PTA), which increases the risk for impaired graft and 
patient survival after RTx. Multiple factors that contribute to late PTA include 
inadequate erythropoietin (EPO) levels, iron deficiency, chronic inflammation, 
transplant-associated medicines, and impaired allograft function. 
 
The prevalence of PTA in pediatric RTx recipients varies between 26% and 83%, 
depending on the definition (hemoglobin, hematocrit) and time of assessment 
(Mitsnefes et al. 2005, Kausman et al. 2004, Kaidar et al. 2014). In adults, the 
reported rates of PTA are around 40% (Molnar et al. 2011a, Vanrenterghem et al. 
2003, Shah et al. 2006). The biphasic pattern is characteristic for the prevalence of 
PTA. Early-onset anemia occurs within the first month after RTx and reaches a 
prevalence of 48–89% (Pascual et al. 2013, Fernandez Fresnedo et al. 2005, Jones 
et al. 2012, Imoagene-Oyedeji et al. 2006). This is partly explained by the 
demanding perioperative period, which is complicated by dilution, blood loss, 
frequent sampling, and poor early graft function (Poesen et al. 2011).  
 
After successful transplantation, early erythropoietin deficiency recovers within the 
first year, resulting in a simultaneous Hb increase (Beshara et al. 1997, Sun et al. 
1989). Usually, late PTA progresses over the following post-transplant years along 
with the deterioration of allograft function. Erythropoietin deficiency due to impaired 
allograft function is suggested as the main mechanism leading to anemia in renal 
transplant recipients (Yabu, Winkelmayer 2011). Other causes of PTA, such as iron 
deficiency, constant low-grade inflammation, and transplant-related medicines 
(immunosuppressants, antihypertensives, antimicrobials) induce the development of 
anemia by several mechanisms. These comprise decreased iron availability for 
erythropoiesis, increased production of erythropoiesis inhibiting inflammatory 
cytokines (Cooper et al. 2003, Molnar et al. 2011b, Molnar et al. 2011a) and 
myelosuppression by antiproliferative immunosuppressants AZA and MMF 
(Mitsnefes et al. 2005). The adverse effects of myelosuppressive drugs manifest in 
cytopenias, such as anemia, leucopenia and thrombocytopenia. Systemic 
inflammation and anemia underlie several chronic diseases and associate with 
impaired graft and patient survival.  
 
Hepatic hepcidin-25, a biologically active 25-amino acid peptide, is the main 
regulator of iron homeostasis that binds to the cellular iron exporter ferroportin, 
limiting the availability of iron for erythropoiesis and circulation (Chan et al. 2013). 
Hepcidin-25 synthesis is induced by inflammation, especially pro-inflammatory 
cytokine IL-6 (Figure 6). Increased hepcidin-25 levels block the duodenal iron 
absorption and iron release from the reticuloendothelial system, which may lead to 
anemia in prolonged inflammatory states (Young, Zaritsky 2009). 
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2.4.5 Long-term outcomes  
An important question is why long-term graft and patient survival of RTx patients 
remains unsatisfactory despite the excellent progression in short-term results, 
diagnostic methods and medications during the past decades (Van Arendonk et al. 
2014, Meier-Kriesche et al. 2004). Toxicity of immunosuppressive medication, virus 
infections (BK polyomavirus), humoral rejections, and non-compliance - all these 
impair the survival rates. Although modern immunosuppressive therapy has 
improved survival rates and led to a reduction in acute rejection rates (Lamb et al. 
2011, Dharnidharka et al. 2014), the long-term outcome of kidney transplant 
recipients continues to be impaired by simultaneous immunosuppression-related 
complications, such as CAI, infections, cardiovascular disease and malignancy 
continuously impair (Alangaden et al. 2006). 
 
According to ANZDATA and NAPRTCS registries, pediatric kidney graft survival at 
1 year exceeds 95% (Dharnidharka et al. 2014). The 5-year graft survival among 
European pediatric kidney transplant recipients is 84% (Lofaro et al. 2016). The 
best (90%) 5-year graft survivals was among pediatric RTx recipients with pre-
emptive transplantation, and poorest (52%) among adolescents with long-term (> 2 
years) dialysis (Lofaro et al. 2016).  In Finland, the survival rates are excellent, with 
5-year graft survival of 90.5% in adult RTx recipients (Peräsaari et al. 2015). In 
children, even the 10-year graft survival exceeds 80%, as shown in Figure 8. 
  
 
Figure 8 Long-term patient and graft survival in pediatric RTx recipients in Finland. 
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CAI is an important factor of graft failure, and of particular interest as there are 
distinct causes of injury at different time points and no effective therapy beyond 
early detection (Smith et al. 2013, Stegall et al. 2015). During the first few years, 
subclinical inflammation and recurrence of the primary disease play a major role, 
whereas alloantibodies and CNI-nephrotoxicity have only a minor role in early graft 
loss (< 5 years post-RTX) (Stegall et al. 2015). 
 
In adults, 20-30% of the allografts will fail within the first 10 years (Stegall et al. 
2015). The rate of premature graft loss is prominent among patients aged 13–25 
years in the US and Canada (Foster 2015), and the risk for graft failure reaches the 
highest point between 17 and 24 years of age, independent of the age at the time of 
RTx (Foster et al. 2011). Risk of graft failure in adolescents and young adults 
increases at the time of transition from pediatric to adult care.  
 
NAPRTCS registry data reports a 10-year patient survival of 91% (93% for a living-
related donor and 88% for a deceased donor). Patient survival has improved 
significantly for living-donor patients, as the 5-year survival in the ‘87-95 era was 
91%, compared to 96% for the ‘96-04 and ‘05-13 eras (NAPRTCS Annual Report 
2014). In Finland, the patient survival rates are excellent as the 10-years patient 
survival exceeds 95% (Tainio et al. 2014). 
 
Infections are an important (20%) cause of death among pediatric recipients, 
followed by other complications, such as cardiovascular disease and malignancies  
(Lofaro et al. 2016, NAPRTCS Annual Report 2014, Holmberg, Jalanko 2015). 
Increased cardiovascular morbidity and mortality are known side effects of 
immunosuppression and important factors for patient death with a functioning graft 
(Mitsnefes 2012, Smith et al. 2013). 
 
Adherence to immunosuppressive therapy is demanding, especially for 
adolescents. The rate of reported nonadherence among pediatric recipients is 
around 30%, and among young adults even two thirds are classified as 
nonadherent (Massey et al. 2015, Dobbels et al. 2010, Shaw et al. 2003). 
Nonadherence increases the risk for acute rejection episodes and graft loss 
(Jarzembowski et al. 2004). Physical and cognitive development and the 
psychosocial functioning of pediatric patients are of highest importance. Real long-
term outcomes in transplant recipients are measured with their ability to integrate 
into society, to study and work, and to raise a family.  Improved outcomes turn the 
focus on complications and quality of life (Griva et al. 2013, Sundaram et al. 2007), 
and thus immunosuppressive therapy should aim to be less toxic and have fewer 
side effects to enable improvements in the quality of life among lifelong users.  
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3 AIMS OF THE STUDY 
The aim of this thesis was to examine the biomarkers of chronic allograft injury in 
pediatric kidney transplant patients. Such markers would enable early identification 
of patients at risk of development of chronic allograft injury and prevent graft loss. 
 
The specific aims of the study were: 
 
1. To assess the incidence of HLA antibodies in pediatric RTx recipients, and 
to analyze the significance of DSA on kidney graft function. 
 
2. To describe the expression of potential immunohistochemically detectable 
biomarkers in kidney graft biopsies, and to correlate these findings to graft 
histology and function.  
 
3. To examine the association of post-transplant anemia and inflammation with 
graft function, and to evaluate the role of underlying anemia-related factors.  
 
4. To assess the prevalence and impact of BKPyV infection on kidney 
transplant function. 
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4 PATIENTS AND METHODS 
4.1 Patients 
The patients included in this thesis underwent kidney transplantation at the 
Children’s Hospital, Helsinki University Hospital, between 1988 and 2014. A total of 
236 pediatric patients received a kidney transplant, and subgroups of 46 to 128 
patients were included into studies I-IV. The patients were followed regularly at the 
transplantation center. Follow-up visits were performed at 3, 6, 12, 18, and 24 
months post-RTx and annually thereafter until the transfer to adult care.  
 
Study I (donor-specific HLA antibodies) included 123 patients who received kidney 
transplants between 1989 and 2004, and had stored plasma samples available for 
HLA analysis and adequate follow-up data for outcome measurements. 
 
Study II (histopathology and biomarkers) included 56 patients transplanted between 
1995 and 2004. All included patients had at least two biopsies available for Banff 
classification and immunohistochemical analyses.  
 
Study III (anemia and inflammation) included 128 patients who were transplanted 
between 1988 and 2006 and had stored sera available for anemia and 
inflammation-related biomarker analyses.   
 
Study IV (polyomavirus infections) comprised 46 patients who received a kidney 
transplant between 2009 and 2014 with adequate monitoring of BK viremia.  
4.2 Methods 
4.2.1 Data collection 
A retrospective collection of clinical data from the patient records included the 
following parameters: disease leading to RTx, date and age at RTx, donor type, 
HLA-A, -B, -DR mismatches, and cold ischemia time. Data on follow-up visits 
included laboratory tests (complete blood count, kidney function tests, and 
inflammation markers) and GFR measurements. GFR was the primary outcome 
measure in all studies (I-IV). Secondary outcomes were change in GFR over time 
and rate of biopsy-proven allograft injury. 
 
HLA typing (HLA-A, -B or -DR) of each patient and kidney donor was determined 
using a serological assay and low-resolution sequence-specific primers (PCR-SSP; 
One Lambda, Inc., Canoga Park, CA) or additional sequence-specific 
Patients and methods 
41 
oligonucleotide probes (PCR-SSO; One Lambda, Inc., Canoga Park, CA). Also, 
ABO compatibility and negative complement-dependent lymphocytotoxicity 
crossmatch (CDC) against donor spleen lymphocytes were required. A mismatch of 
2/1 (A and B loci/DR locus) or better was achieved in over 90% of the patients.  
 
Immunosuppression was based on triple-drug immunosuppression including CNI 
(CsA or Tac), antimetabolite (AZA or MMF) and methylprednisolone. Combinations 
and dosing were individualized based on patient characteristics. Induction therapy 
with basiliximab was used since 2000.  
 
Acute rejections were diagnosed by core needle and fine needle biopsies until the 
year 2000. Thereafter, only core needle biopsies were used for diagnosis. Episodes 
with clinical findings and biopsy verification were treated with intravenous 
methylprednisolone (10 mg/kg/day for 3-5 days).  
 
Kidney graft function was followed by measured GFR using 51Cr-EDTA clearance 
with modified Brochner-Mortensen equation normalized to a standard body surface 
area of 1.73 m2 (Brochner-Mortensen et al. 1974, Haycock et al. 1978). The 
distribution values between 15% and 35% were acceptable. The annual GFR 
decline (mL/min/1.73 m2/year) was assessed for every patient from 1.5 post-
transplant years to lthe ast follow-up visit. CKD stages were used as follows: GFR > 
60 mL/min/1.73 m2 (stages 1-2), GFR 30–59 mL/min/1.73 m2 (stage 3), GFR < 30 
mL/min/1.73 m2 (stages 4–5). Graft failure was defined as a return to dialysis. 
4.2.2 Measurement of HLA antibodies using Luminex assay (I) 
HLA class I (HLA-A, -B, -Cw) and class II (HLA-DR, -DQ, -DP) antibody screening 
was performed retrospectively, using LABScreen Mixed screening assay according 
to manufacturer’s instructions (LABType, One Lambda, Canoga Park, CA). Positive 
samples required further analysis with LabScreen single antigen kits to specify 
antigen positivity and were assigned using HLA Visual software (One Lambda). 
Assigned antibodies were compared to donor HLA type to identify DSA. The 
strength of donor-specificity was determined using mean fluorescence intensity 
(MFI).  MFI values > 500 were considered positive. 
4.2.3 Histopathology (II, IV) 
Percutaneous core needle biopsies were taken according to protocol at 3, 18 and 
36 months or when indicated on clinical grounds, i.e., significantly decreased GFR, 
increased serum creatinine, or suspected acute rejection. Biopsy tissue samples 
were fixed in formaldehyde, embedded in paraffin and cut into thin 3–4 μm sections 
for staining. Routine stains for light microscopy included hematoxylin and eosin, 
Masson’s trichrome, periodic acid-Schiff (PAS), and methenamine silver PAS. 
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Routine histopathologic analyses were performed by a pathologist according to the 
Banff criteria. An additional scoring was blindly performed by one of the co-authors 
according to Banff’05 criteria, and in selected cases, consensus-reading sessions 
were arranged with an experienced pathologist without knowledge of any clinical 
data (II). Combination of interstitial fibrosis (IF) and tubular atrophy (TA) scores was 
used to define chronic changes in allograft histology. 
4.2.4 Immunohistochemistry (II, IV) 
Immunoperoxidase stainings were performed using routine methods according to 
manufacturer’s instructions for vimentin, alpha-smooth muscle actin (α-SMA), 
collagen IV, and P-selectin glycoprotein ligand-1 (PSGL-1) (Table 9). Biopsies from 
histologically normal kidneys that were removed due to other diseases than cancer 
were used as normal controls. Additional immunohistochemistry for C4d staining 
was performed routinely, and for polyomavirus (SV40T) when requested. Positivity 
was reported as present or absent. Positive nuclear immunoperoxidase staining for 
SV40 large T antigen (LTag) in a graft biopsy was diagnostic for PyVAN due to 
cross-reactivity among LTags of BKPyV, JCPyV and SV40 (IV).  
Table 9. Antibodies used in immunohistochemical stainings in study II 
Antibody Manufacturer Clone/Code Dilution 
Vimentin  DakoCytomation 3B4/M7020 1:100 
α-SMA DakoCytomation 1A4/M0851 1:400 
Collagen IV DakoCytomation CIV 22/M0785 1:50 
PSGL-1 Santa Cruz Biotech Sc-13535 1:500 
α-SMA, alpha-smooth muscle actin; PSGL-1, P-selectin glycoprotein ligand-1; DAB, 3,3'-
diaminobenzidine. 
 
Microscopy and semiquantitative scoring of immunopositivity (II) was performed 
using a standard Leica DM RX microscope and 20x magnification. Peritubular 
PSGL-1 infiltrates, vimentin expression in tubular epithelial cells, proportion of α-
SMA positive peritubular areas and collagen IV deposition in the interstitium were 
scored semiquantitatively from 0 to 3 (0, no staining; 1, comparable to normal 
controls < 10%; 2, mildly increased 10 to 24%; and 3, moderately to severely 
increased > 25% of renal cortex involved). In the statistical analyses, the scores 0–1 
and 2–3 in the biomarker expression were defined as low and high, respectively.  
4.2.5 Enzyme-linked immunosorbent assay (III, IV) 
Enzyme-linked immunosorbent assay (ELISA) was used to determine serum 
concentrations of the inflammation markers hsCRP and IL-6, and of the anemia 
markers EPO and hepcidin-25 from stored serum samples. Analyses were 
performed according to the manufacturer’s protocol using the following kits: 
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Biovendor (Karasek, Czech Republic) for EPO, DRG (Marburg, Germany) for 
hepcidin-25, Circulex (Nagano, Japan) for hsCRP, and Diaclone (Besancon, 
France) for IL-6. Cut-off values for the inflammatory marker hsCRP were set at 
hsCRP < 1 mg/L, hsCRP 1–3 mg/L and hsCRP > 3 mg/L, as previously described 
(van Ree et al. 2007, Dahle et al. 2011).  
4.2.6 BKPyV monitoring by PCR (IV) 
Patients were monitored for BK viremia every 3 to 6 months during the first 1.5 
years and annually thereafter according to modified KDIGO guidelines (Kidney 
Disease: Improving Global Outcomes (KDIGO) Transplant Work Group 2009). 
Quantitative PCR was used to screen plasma BKPyV load in viral genome copies 
per milliliter as described previously (Dumoulin, Hirsch 2011). The lower limit for 
positivity was viral load of > 400 copies/mL and clinically significant limit of > 10,000 
copies/mL in plasma (Hirsch et al. 2014).  
4.2.7 Statistical analyses 
Results are expressed as means ± standard deviations (SD) for continuous 
variables with normal distribution, and as medians and interquartile ranges (IQR) for 
parameters with skewed distribution. Statistical significance of differences between 
the groups was tested by t-test and ANOVA or Mann-Whitney U test, Kruskall-
Wallis and chi-square tests, where appropriate. Univariate Pearson’s correlation 
coefficient and Spearman rank test were used to assess the associations between 
variables. Abnormally distributed values were log-transformed before the linear 
regression analyses. Multivariable regression analyses were performed to identify 
independent predictors of continuous variables. Two-sided p-values < 0.05 were 
considered as statistically significant. All statistical analyses were performed using 
SPSS version 20.0 (IBM, Armonk, NY).  
4.2.8 Ethical considerations 
The Ethics Committee for Pediatrics, Adolescent Medicine and Psychiatry of the 
Helsinki and Uusimaa Hospital District approved the study protocol (86/2007, 
126/2007, 269/2009, 22/E7/2007). 
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5 RESULTS 
The clinical characteristics of the pediatric RTx recipients included in studies I–IV 
are described in detail in Table 10.  
 
Table 10. Characteristics of the pediatric RTx patients included into the studies I–IV 
  I II III IV 
Study period, years 1989–2004 1995–2004 1988–2006 2009–2014 
Number of patients 123 56 128 46 
Gender, male, n (%) 80 (65) 38 (68) 84 (66) 28 (61) 
Age at transplantation, yr 4.4 (1–18) 6.3 (1–15) 3.8 (1.7–9.3) 4.3 (1–18) 
Cause of ESRD, n (%)     
 CNF 47 (38) 19 (34) 61 (48) 20 (44) 
 CAKUT 31 (25) 21 (37) 28 (22) 7 (15) 
 Other hereditary 22 (18) 11 (20) 20 (16) 6 (13) 
 Inflammatory 11 (9) 0 8 (6) 4 (9) 
 Other 12 (10) 5 (9) 11 (9) 9 (20) 
HLA-MM, mean±SD     
 A/B 1.5 ± 0.8  1.4 ± 0.9 1.6 ± 0.9 1.9 ± 0.9 
 DR 0.7 ± 0.5 0.7 ± 0.5 0.7 ± 0.6 1.0 ± 0.5 
LD, n (%)   32 (26) 14 (25) 34 (27) 21 (46) 
Cold ischemic time, hours 18.8  15.9  18.4  9.7  
CMV D+/R-, n (%) 51(41) 23 (44) 51 (40) 18 (39) 
Graft outcome     
 Follow-up, years 6.7 (4–20) 7.4 (1–10) 10 (7–14) 2.3 (1–6) 
 Graft loss, n 10 4 11 2 
CNF, congenital nephrotic syndrome of the Finnish type; CAKUT, Congenital anomalies of the kidney 
and urinary tract; HLA-MM, HLA-mismatches; LD, living donor; CMV, cytomegalovirus; D+/R-, donor 
seropositive / recipient seronegative.  
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5.1 Donor-specific HLA antibodies (I) 
5.1.1 HLA antibodies  
Post-transplant HLAab findings were correlated to graft function and clinical 
outcome in 123 patients transplanted at the median age of 4.3 years and followed 
for over 10 years. HLAabs were measured retrospectively from samples (average of 
2.4 samples per patient) that were routinely collected at different time points after 
RTx. Nearly two-third (64%) of the 123 patients had detectable HLAabs in half 
(140/294) of the samples. The proportions of HLAabs were comparable at different 
time points. Nearly half (44%) of the detectable HLAabs were donor-specific (DSA), 
whereas the other half were non-DSA (Table 11).  
 
Table 11. HLA antibodies in pediatric renal transplant recipients 
HLAab finding Samples Patients 
Total 294 123 
HLAab negative 154 (52%) 44 (36%) 
HLAab positive 140 (48 %) 79 (64 %) 
 Non-DSA positive 78 37 
 DSA positive 62 42 
  Class I 15 12 
  Class II 40 23 
  Class I+II 7 7 
HLA, human leukocyte antigen; HLAab, HLA antibody; DSA, donor-specific HLA antibody. 
5.1.2 Patients with DSA 
DSA was detectable in 62 (21%) samples, and the proportion of DSA positive 
samples increased somewhat with time. Overall, DSA positivity was detectable in 
42 (44%) patients. Most (55%) DSA antibodies reacted against class II antigens. 
DSA positivity fluctuated over time, but appeared always against the same antigen 
specificity in consecutive samples. The background data of the patients were 
comparable between DSA-positive and DSA-negative patients. However, early (< 3 
months) immunoactivation was more common (71%) among patients with DSA 
compared to immunoactivation (46%) in those without any detectable HLA antibody 
(p = 0.035). Five patients had detectable DSA (MFI levels 613, 1671, 1825, 2033, 
and 9064) before the late (> 3 months) acute rejection episode. Overall, late acute 
rejection episodes were treated in 21% (9/42) and 23% (10/44) of the patients with 
DSA and without HLA abs at any time, respectively. 
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5.1.3 DSA and graft function 
The distribution of individual GFR values at the time of HLA antibody detection was 
similar in patients with and without HLAab or DSA, as shown in Figure 9. Even 
patients with high DSA antibody titers had variable GFR, which did not differ 
significantly from the other patient groups. 
 
Figure 9 Individual glomerular filtration rate (GFR) (mL/min/1.73 m2) values at the time of post-
RTx HLA detection. Dashed lines, ±2 SD for GFR of HLAab negative patients. 
 
Detection of DSA did not associate with poor graft function in any time period of 0–2 
years, 3–5 years or 6–10 years post-RTx (Table 12). Similarly, the annual GFR 
decline after HLAab detection was comparable between patient groups, and future 
graft function showed similar tendency regardless of the antibody finding (Table 12). 
 
Table 12. Glomerular filtration rate (GFR) at the time of HLA antibody detection in time 
periods of 0–2, 3–5 and 6–10 years after RTx, and annual GFR decline 
(ΔGFR) 
 GFR (mL/min/1.73 m2) 
 0–2 yrs 3–5 yrs 6–10 yrs ΔGFR /year 
HLAab negative 63 ± 19 (78) 60 ± 19 (46) 39 ± 10 (22) 2.6 ± 3.7 
Non-DSA positive 62 ± 20 (40) 50 ± 16 (22) 44 ± 15 (13) 2.8 ± 4.2 
DSA positive 58 ± 25 (21) 55 ± 22 (18) 40 ± 13 (22) 1.3 ± 4.3 
Values are presented as mean ± SD (n). DSA, donor-specific HLA antibody; ΔGFR, annual GFR 
decline (mL/min/1.73 m2/year).  
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5.1.4 DSA and biopsy findings  
Post-RTx DSA positivity during the first three years was not significantly associated 
with chronic lesions (IF/TA) in protocol biopsies. Protocol core needle biopsy and 
simultaneous HLA ab measurement at 1.5 years and 3 years post-RTx were 
available from 64 and 75 patients, respectively. At 1.5 years post-RTx, chronic 
lesions were detected in 20 (31%) samples, associating with previous DSA positivity 
in five patients. At 3 years post-RTx, IF/TA lesions were observed in nearly half 
(47%) of the biopsies and were comparable between patients with and without DSA 
positivity (53% vs. 43 %, p = 0.450).  
 
An interesting question was what happens to graft function in patients with DSA 
positivity and chronic histological lesion during the first three years after RTx. The 
mean GFR in patients with DSA positivity and IF/TA lesions decreased 5–15 
mL/min/1.73 m2 compared to GFR in patients with normal biopsy findings, as shown 
in Table 13. However, the GFR was comparable to that of patients with chronic 
lesions without DSA, suggesting that chronic lesions, not antibody findings, 
correlated with the lower GFR values. 
 
 
Table 13. Long-term graft function measured as glomerular filtration rate (GFR, 
mL/min/1.73 m2) in relation to post-transplant DSA finding at 0–3 years and 
biopsy finding at 1.5 or 3 years post-RTx 
DSA, biopsy  GFR (mL/min/1.73 m2) 
0–3 years 3 yrs (n=95) 5 yrs (n=84) 7 years (n=61) 10 years (n=32) 
DSA-, normal  64 ± 16 (35) 58 ± 15 (29) 51 ± 14 (22) 44 ±10 (10) 
DSA+, normal 56 ± 18 (11)* 54 ± 16 (11) 42 ± 15 (9) 40 ± 11 (6) 
DSA-, IF/TA 52 ± 18 (36) 51 ± 16 (33) 47 ± 13 (23) 33 ±14 (10) 
DSA+, IF/TA  49 ± 18 (13) 49 ± 14 (11) 43 ± 14 (7) 34 ± 9 (6) 
DSA, donor-specific HLA antibody; IF/TA, interstitial fibrosis and tubular atrophy. *DSA+normal vs. 
DSA+ IF/TA, p = 0.040.  
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5.2 Histopathology and immunohistochemistry (II) 
Histopathology and the expression of four biomarkers were studied in kidney graft 
biopsies to correlate biomarker findings to concomitant and subsequent graft 
function. A representative staining pattern of the biomarkers PSGL-1, vimentin, α-
SMA and collagen IV is shown in Figure 10. 
 
 
Figure 10 Immunohistochemical staining pattern of a) PSGL-1, b) vimentin, c) α-SMA, and d) 
collagen IV in the kidney graft biopsy. Interstitial PSGL-1 expression in the areas of 
inflammation, vimentin expression in tubular cells, and α-SMA and collagen IV 
expression in the interstitium.  
5.2.1 Biomarker findings 
Histopathology and biomarker scores were comparable in both protocol (75%, 
123/165) and indication (25%, 42/165) biopsies. Only the correlation between 
biomarker scores and IF/TA decreased in indication biopsies. Overall, IF/TA lesions 
were common and increased with time. Mean Banff scores for inflammation, 
tubulitis, arterial hyalinosis and arterial sclerosis were 0.53±0.75, 0.47±0.75, 
0.09±0.28, and 0.40±0.72, respectively. 
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Table 14. Banff scores in relation to biomarker expression in biopsies post-RTx 
Banff score Vimentin α-SMA Collagen IV PSGL-1 
Tubulitis (t) 0.170 0.118 -0.002 0.409 ** 
Interstitial inflammation (i) 0.153 0.138 0.134 0.415 ** 
Arteritis (v) 0.121 0.239 * 0.077 0.246 * 
Glomerulitis (g) -0.106 0.168 - - 
Interstitial fibrosis (ci) 0.245 * 0.370 ** 0.416 ** 0.303 * 
Tubular atrophy (ct) 0.334 * 0.402 ** 0.516 ** 0.348 * 
Glomerulopathy (cg) 0.101 0.045 0.119 -0.007 
Mesangial matrix increase (mm) 0.179 0.233 * 0.166 0.247 * 
Arterial sclerosis (cv) 0.156 0.251 * 0.126 0.197 
Arterial hyalinosis (ah) 0.157 0.116 0.089 0.128 
Spearman correlation, * p < 0.05, ** p < 0.001.  
 
 
Immunohistochemical staining for the interstitial biomarkers α-SMA and collagen IV 
increased with time, similarly to IF/TA lesions. The expression of PSGL-1 and 
tubular vimentin was unrelated to time, although all four biomarkers correlated with 
the accumulation of fibrosis (Table 14). Overall, the biomarker scores were 
significantly higher in IF/TA positive biopsies compared to IF/TA negative biopsies 
(Table 15).  
 
Table 15. Biomarker expression in biopsies with and without IF/TA lesions 
Biomarkers IF/TA negative IF/TA positive p 
PSGL-1 1.0 ± 0.6 (63) 1.6  ± 0.7 (50) < 0.001 
Vimentin 0.8  ± 0.6 (69) 1.0  ± 0.6 (46) 0.011 
α-SMA 1.4  ± 0.7 (61) 2.0  ± 0.9 (50) < 0.001 
Collagen IV 0.9  ± 0.8 (71) 1.7  ± 1.0 (51) < 0.001 
IF/TA, interstitial fibrosis/tubular atrophy; PSGL-1, P-selectin glycoprotein ligand-1; α-SMA, alpha-
smooth muscle actin. 
5.2.2 Biopsies and graft function 
Patients were divided into two groups according to biomarker scores (0–1 vs. 2–3) 
to evaluate the predictive value of each marker on GFR. At the time of the 1.5-years 
biopsy, patients with high (2–3) IF/TA or collagen IV scores showed decreased 
mean GFR (IF/TA: 50 vs. 68 mL/min/1.73 m2, p = 0.004; Collagen IV: 45 vs. 65 
mL/min/1.73 m2, p = 0.016) compared to those with lower (0–1) scores. The other 
biomarkers showed similar, although statistically insignificant tendency.  
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Early findings at 3-month biopsies were comparable between patients with low and 
high biomarker scores. However, the predictive value of 1.5-year biopsies was 
moderate as higher scores of IF/TA, collagen IV and vimentin associated with 
decreased GFR (Figure 11). In fact, the multivariable analysis revealed that none of 
the biomarkers showed superior predictive value for late graft function compared to 
routine IF/TA score according to Banff classification. Furthermore, the annual GFR 
decline was comparable between groups with low and high biomarker expression.  
 
 
 
Figure 11 Glomerular filtration rate (GFR, mL/min/1.73 m2) at the time of biopsy, 3, 4 and 5 years 
after RTx in patients with low and high IF/TA, collagen IV and vimentin scores in 1.5-
year protocol biopsies. 
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5.3 Anemia and inflammation (III) 
The association between post-transplant anemia, low-grade inflammation and 
allograft function of 128 pediatric RTx recipients transplanted between 1988 and 
2006 was studied in a retrospective, observational analysis of a number of blood 
samples and their correlation with graft function.  
5.3.1 Prevalence of post-transplant anemia 
The prevalence of anemia was 55% at 1 year and 49% at 10 years after RTx 
(Figure 12). The degree of anemia was mainly (73%) moderate (Hb > 100 g/L), and 
the prevalence of severely anemic patients decreased from 17% at 1 year to 5% at 
10 years post-transplant.  
 
Figure 12 The prevalence (%) of anemic samples after RTx. Anemia (white bars) and severe (Hb < 
100 g/L) anemia (light grey bars). 
5.3.2 Biopsy findings and graft function 
At the time of protocol biopsy at 1.5 and 3 years, anemia was detected in half 
(16/32) of the patients with fibrosis compared to 17 % (3/18) in those without fibrosis 
(p = 0.033). The mean levels of Hb were 115 ± 12 g/L and 121 ± 13 g/L, 
respectively (p = 0.034). Low Hb levels even preceded graft fibrosis in patients who 
developed fibrosis after the first 3-month biopsy.  
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Compared with their non-anemic counterparts, the graft function of anemic patients 
was significantly lower from 6 months to 8 years post-RTx (Figure 13). The patients 
with good graft function (GFR > 60 mL/min/1.73 m2) had a median Hb value of 119 
g/L, whereas those with GFR of 30–60 mL/min/1.73 m2 and GFR < 30 mL/min/1.73 
m2, had significantly lower Hb levels of 114 g/L and 112 g/L, respectively (p < 
0.001). In addition, the patients with anemia at 1.5 post-RTx years had significantly 
decreased subsequent GFR until 8 post-RTx years. Hemoglobin concentration was 
strongly related to concomitant and future GFR. 
 
Figure 13 Mean hemoglobin level in patients with and without anemia at the time of study point.  
5.3.3 Anemia-related factors 
Iron profile was assessed in 22% of the patients, and iron deficiency was observed 
in a total of 14%. Microcytosis was present in only 1% of the samples. Leucopenia 
and thrombocytopenia were more common (11%) and associated with simultaneous 
anemia (p<0.01) (Figure 14). Overall, pancytopenia was infrequent.  
 
Erythropoietin (EPO) levels were measured in a sample collected at 1.5-4 years 
after RTx. Interestingly, the median EPO levels were higher in anemic samples 
compared to those with normal Hb (7.7 vs. 5.6 mIU/mL, p = 0.038), and serum EPO 
level showed an inverse correlation with Hb concentration (r = - 0.206, p = 0.038). 
EPO levels were unrelated to concomitant GFR (r = 0.025, p = 0.818) and 
comparable across CKD stages (p = 0.351).  
 
Hepcidin-25 levels were also measured at the maintenance phase 1.5–4 years after 
RTx. Hepcidin-25 was unrelated to Hb level (r = −0.052, p = 0.603), but inversely 
correlated with concomitant GFR (r = −0.305, p = 0.006). Hepcidin-25 level at 1.5–2 
years predicted GFR at 6 years (r = −0.336, p = 0.001). 
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Figure 14 The prevalence of anemia-related factors in samples with anemia (A+) and with normal 
Hb (A-), * p < 0.005. 
5.3.4 Low-grade inflammation 
The inflammatory markers hsCRP and IL-6 were measured repeatedly to analyze 
the role of low-grade inflammation in allograft function. Inflammatory status was 
assessed in 731 samples drawn at various time points during the 10-year follow-up, 
with the median hsCRP value of 0.40 (IQR 0.2-1.5) mg/L, IL-6 value of 1.40 (IQR 
0.2-5.0) and ESR of 19 (IQR 12-30) mm/hr. Elevated hsCRP levels tended to 
associate with decreased GFR, but only early after RTx. Similarly, ESR increased 
along the CKD stages and showed an inverse correlation with GFR, although in 
univariate analysis only. None of these markers of inflammation showed a clear 
significant correlation with concomitant or subsequent graft function. 
 
The median hsCRP level was higher in anemic samples compared to those with 
normal Hb (0.43 vs. 0.39 mg/L, p = 0.019). Accordingly, hsCRP and Hb showed a 
weak inverse correlation (r = -0.095, p = 0.010), which was prominent in the early 
post-transplant period (at 6 mo: r = -0.339, p = 0.024). Surprisingly, hsCRP also 
correlated with serum EPO level (r = 0.263, p = 0.007). IL-6 levels were unrelated to 
Hb level (r = -0.045, p = 0.265) and GFR (r = -0.041, p = 0.694), whereas ESR 
showed a strong inverse correlation with Hb level (r = -0.383, p < 0.001) and GFR  
(r  = −0.276, p = 0.005) at 1.5–2 years after RTx. 
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5.4 BK polyomavirus (IV) 
5.4.1 BK viremia 
BK polyomavirus infection was studied in 46 kidney transplant recipients whose 
plasma was continuously monitored for BK viremia. During a median of 4 years of 
follow-up, 9 patients had a peak plasma BKPyV PCR >400 copies/mL in routine 
screening samples. BK viremia occurred at a median of 6 (range 3–22) months 
post-RTx with a median BKPyV load of 4,555 (IQR 1,350-17,300) copies/mL. All 
these patients had positive BKPyV PCR in at least two samples. Three patients had 
a high level (> 10,000 copies/mL) BK viremia, with a median peak BKPyV viral load 
of 61,500 copies/mL. High BK viremia occurred at a median of 6 (range 3–9) 
months post-RTx and lasted from 1 to 5 months. Background data and presumed 
risk factors of post-transplant BK viremia are presented in Table 16.   
 
 
Table 16. Background data on patients with and without detectable BK viremia during 
the follow-up 
 BK viremia (n=9) No BK viremia (n=37) p-value 
Male gender, n 4 (44%) 24 (65%) 0.284 
Age < 5 years at RTx, n 4 (44%) 20 (54%) 0.718 
Living donor, n 4 (44%) 17 (47%) 0.881 
Tacrolimus at discharge, n 3 (33%) 7 (19%) 0.384 
Mycophenolate at discharge, n 2 (22%) 4 (11%) 0.581 
Post-transplant DSA, n 3 (33%) 5 (14%) 0.176 
Median plasma creatinine (umol/L)   
 3 mo 75 (59-107) 49 (35-78) 0.121 
 6 mo 76 (54-92) 48 (34-83) 0.256 
 12 mo 85 (57-112) 47 (38-89) 0.128 
 24 mo 54 (50-77) 45 (36-75) 0.302 
 36 mo 55 (42-77) 52 (42-78) 0.765 
Median GFR (mL/min/1.73 m2)   
 3 mo 55 (41-61) 67 (57-82) 0.030 
 6 mo 58 (43-62) 60 (51-75) 0.288 
 12 mo 64 (36-77) 62 (53-74) 0.750 
 24 mo 60 (41-82) 68 (48-71) 0.874 
 36 mo 56 (41-63) 63 (58-76) 0.047 
Values in table are presented as n (%) or median (interquartile range, IQR). DSA, donor-specific HLA 
antibodies; GFR, glomerular filtration rate. 
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5.4.2 BKPyV and graft function 
Early GFR at 3 months post-RTx was available from 38 (83%) patients, of whom 6 
with early BKPyV replication (> 400 copies/mL) showed significantly decreased 
median GFR compared to 32 patients without BK replication (55 vs. 67 mL/min/1.73 
m2, p = 0.030) (Table 16). Similar, though statistically non-significant tendencies 
were seen in viremic patients at 6 months (58 vs. 60 mL/min/1.73 m2, p = 0.288) 
and 12 months (64 vs. 62 mL/min/1.73 m2, p = 0.750) post-RTx. At the time of high 
BKPyV load (> 10,000 copies/mL, five samples), cystatin C level increased to a 
mean of 2.1 ± 0.4 mg/L compared to 1.4 ± 0.3 mg/L in 18 samples with a moderate 
(400–10,000 copies/mL) BKPyV load (p = 0.007). The long-term graft function of 
four patients with BKPyV viremia is demonstrated in Figure 15. 
 
Figure 15 Long-term GFR (mL/min/1.73 m2) in four patients (a–d) with post-transplant BK viremia. 
Grey bars indicate the level of BKPyV viremia (copies/mL) and the black line 
demonstrates mean GFR (mL/min/1.73 m2) in relation to time (months) since RTx. 
5.4.3 Polyomavirus-associated nephropathy  
PyVAN developed in three patients during the first year post-RTx. One patient with 
PyVAN had simultaneous high BK viremia, whereas the other patient had high viral 
loads of JCPyV DNA in urine without detectable BKPyV replication in urine or 
plasma, as previously reported (Lautenschlager et al. 2014). In addition, one patient 
with BK viremia had BKPyV DNA extracted from biopsy, although the preceding 
SV40 staining remained negative. Two of these grafts were lost later due to ABMR.  
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6 DISCUSSION  
This thesis evaluates noninvasive biomarkers of chronic allograft injury and long-
term graft function in pediatric RTx recipients. The studies were retrospective, 
longitudinal and observational analyses of biomarkers that reflect the activation of 
immune response and the consequences of immunosuppression after kidney 
transplantation. The results showed that post-transplant HLA antibodies were 
common, but the detection of DSAs, as such, did not predict poor GFR at the time 
of sampling or later on. Fibrosis associated with decreased graft function and 
increased biomarker scores, but none of the biomarkers showed a superior 
predictive value for long-term graft function compared to routine IF/TA score. 
Anemia was related to poor graft function, which could not be explained by distinct 
low-grade inflammation or evident erythropoietin deficiency. In addition, BK 
polyomavirus infection associated with long-term complications, such as ABMR and 
allograft injury.  
6.1 Can we predict graft function by detecting DSA? (I) 
During the past decade, the significance of DSAs in chronic ABMR and poor graft 
survival has been well emphasized (Sellares et al. 2012, Hidalgo et al. 2009, Lee et 
al. 2009, Dunn et al. 2011). It is evident that sensitized recipients have a high risk 
for ABMR (Susal et al. 2009, Lucia et al. 2015), but also previously nonsensitized, 
low-risk recipients may develop post-transplant dnDSAs, which increases the risk 
for chronic ABMR and graft loss (Ginevri et al. 2012, Wiebe et al. 2012, Chaudhuri 
et al. 2013). In particular, pre-transplant DSAs increase the incidence of early 
ABMR from 1–6% to 21–55% (Amico et al. 2009, Lefaucheur et al. 2007, Kraus et 
al. 2009). Other independent predictors of early rejections are non-adherence to 
immunosuppression and HLA class II mismatches (Wiebe et al. 2012). 
Recommendations for post-transplant screening of dnDSA have suggested 
individual adaptation of immunosuppression in patients with DSA according to risk 
profile (Tait et al. 2013), but a recent cost-benefit analysis revealed only limited 
efficacy of screening stable recipients (Kiberd et al. 2016).  
 
After publication of study I, the role of dnDSA on graft loss has been extensively 
studied in adult cohorts. We measured post-RTx HLAab in a pediatric cohort and 
correlated the detection of individual DSA with graft function. The clinical 
importance of post-transplant DSA on graft outcome is evident (Susal et al. 2015, 
Wiebe, Nickerson 2013, Loupy et al. 2012), but requires critical consideration 
together with other factors, such as age at RTx and nonadherence, when aimed to 
improve long-term survival (Sellares et al. 2012). Also, patients with combined 
TCMR and ABMR have unfavorable outcomes (Willicombe et al. 2014). Prospective 
multicenter studies of adult RTx recipients showed poor graft survival in patients 
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with dnDSA (Terasaki et al. 2007, Wiebe et al. 2012). The survival rate was 58% in 
patients with dnDSA compared to 81% in those without (Terasaki et al. 2007). 
However, no pretransplant DSA feature (class, number, MFI) reliably predicts graft 
outcome (Amico et al. 2009, Lefaucheur et al. 2010). And most importantly, many 
patients with DSA still have moderate outcome for years (Konvalinka, Tinckam 
2015).  
 
Interestingly, the optimal timing for post-transplant antibody testing, definitive 
treatment strategies, and the latency between the detection of DSA and clinical 
effect (i.e. graft dysfunction or histological injury) are still incompletely understood 
(Konvalinka, Tinckam 2015). We studied serum samples taken at various time 
points and detected a slight increase in the frequency of DSA over time.  Detection 
of DSA was common in children, and was interestingly unrelated to a marked 
annual decline in GFR. Future determination of clinically feasible treatment 
strategies for stable patients with dnDSA requires a clinical trial (Archdeacon et al. 
2011). 
 
The cause of late allograft loss is often attributable to immune mediated chronic 
injury, detected as glomerulopathy, IF/TA with or without rejection, or polyomavirus 
nephropathy (El-Zoghby et al. 2009). The importance of alloimmunity is evident, 
although the specific mechanism of late ABMR, and especially the role of 
predominant class II DSA, remain somewhat unclear. Also, complement-fixing 
DSAs and C1q testing have been of special interest due to associations with poor 
outcomes (Loupy et al. 2013, Sutherland et al. 2012), and the IgG3-dominant (with 
the highest MFI level) DSA subclass associates with allograft failure (Lefaucheur et 
al. 2016). Focusing on these subtypes of DSA may be helpful to identify clinically 
relevant phenotypes of antibody-mediated injury. In our study, DSA reacted mostly 
against class II antigens and non-DSA against class I, as also reported in adults 
(Lachmann et al. 2009). When the results of adult studies are applied to pediatric 
cohorts it is important to note that B-cell subpopulations, which participate in the 
regulation of a variety of immune responses, mature with age (Smet et al. 2011). 
 
To date, data on DSA in pediatric recipients are still scarce. According to two recent 
pediatric studies, one-third of the pediatric recipients have detectable dnDSA, which 
reacts mainly (70%) against class II antigens (Kim et al. 2014, Comoli et al. 2016). 
The rates of DSAs are similar to our finding (34%) with high prevalence of class II 
(65%) DSA. These rates are higher than reported (20%) in adult cohorts (Wiebe et 
al. 2012, Everly et al. 2013). This could be partly explained by noncompliance, 
stronger alloreactivity in children, or high sampling frequency (Comoli et al. 2016).  
 
An important question is what to do with stable patients with detectable DSA after 
RTx. A recent study of complement fixing dnDSAs in a pediatric cohort suggests the 
removal or modulation of antibodies already at the time of the first confirmed 
positivity, since 60% of the patients with persistent DSA show ABMR (Comoli et al. 
2016). However, the role of fluctuating DSA levels over time is incompletely 
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understood (Wiebe et al. 2012, Cooper et al. 2011). In our study, fluctuation was 
evident, although the limited number of sera per patient did not allow further 
analysis. Similarly, almost half of the DSAs became undetectable in another 
pediatric cohort (Kim et al. 2014). Also, Kimball et al. suggest longitudinal 
monitoring of DSA, as they showed favorable outcomes for patients who were able 
to eliminate DSA after RTx (Kimball et al. 2011). 
 
The diagnostic criteria of AMBR were currently revised, and the C4d negative 
ABMR was included in the Banff’13 classification (Haas et al. 2014). Our results 
lacked the staining for C4d, which hampered the differentiation and classification of 
cellular and antibody-mediated episodes at that time. However, we found that 
IF/TA-findings in biopsies at 1.5 and 3 years post-transplantation correlated with 
poor outcome later on, but these lesions were not more prevalent in patients with 
DSA during the first three years. In accordance with this, the detection of DSA did 
not associate with marked chronic lesions in biopsies at 1.5 or 3 years or with a 
significant decrease in GFR at 3–10 years post-RTx. The wide distribution of GFR 
at the time of DSA detection was not different from that in patients without DSA. 
 
Two pediatric studies reported increased plasma creatinine in DSA-positive 
recipients (Ginevri et al. 2012, Chaudhuri et al. 2013), and one showed poor graft 
function using Kaplan-Meier survival analysis (Kim et al. 2014). Interestingly, they 
reported that DSA-positive patients showed a more rapid decline in GFR, but other 
factors, such as microvascular injury, were independent risk factors for poor graft 
outcome in the multivariable analysis (Kim et al. 2014). The authors proposed a 
graded response to DSA MFI, in which the low MFI might resolve and the high MFI 
associate with poor GFR. Of note, no specific threshold for DSA positivity has yet 
been clearly established, but these results support the current concept of 
prospective HLAab monitoring also in pediatric patients. In our study cohort, one-
third (23/62) of the DSA positive samples had MFI > 10,000, which was, however, 
unrelated to poor graft function later on. Moreover, the annual decline in GFR was 
comparable despite the antibody finding.  
 
The adaptation of immunosuppression in the presence of high MFI levels might 
support the main aim to prevent the development of harmful microvascular injury. 
An ongoing clinical trial is performing a systemic evaluation of this concept (Dorling 
et al. 2014), and the interpretation of the results of a recent cost-benefit study 
(Kiberd et al. 2016) may specify the future focus of post-transplant monitoring of 
DSA. Our retrospective study design did not allow any adaptation to 
immunosuppression, and thus our findings reflect the natural course of clinical 
events and GFR, when no change was made due to DSA. The fact that no therapy 
is validated for patients with dnDSA puts the relevance of post-transplant monitoring 
of DSA in clinically stable patients into question (Tait et al. 2013, Roelen et al. 
2012). The adaptation of immunosuppression has become a common policy in 
many transplant centers, although it partly hampers the goal to minimize 
immunosuppression.  
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6.2 Clinical value of immunohistochemical biomarkers (II) 
CAI is a multifactorial process that develops over time and leads to excessive 
accumulation of extracellular matrix (ECM) and renal fibrosis. Early biomarkers are 
needed to detect the early molecular changes in cell structure, before the 
irreversible changes in visual histopathology (Birk 2012). The analysis of 
independent or supplement markers is essential to increase the diagnostic ability of 
biopsies to detect subclinical pathology.  
 
To date, neither immunohistochemistry nor molecular techniques are able to 
differentiate reliably between IF/TA with different causes. The most accurate way is 
to combine clinical history, serology and histology to distinguish rejections, BKPyV-
associated nephropathy, and recurrent or de novo diseases (Haas 2014). Protocol 
biopsies demonstrate the cumulative impact of donor factors on early IF/TA 
(Henderson et al. 2011). Early tubulointerstitial injury is detectable and precedes 
chronic IF/TA changes while the graft function is still normal. Thus, biomarkers that 
could visualize early injury would allow early interventions to slow down the 
development of fibrosis.   
 
Epithelial-to-mesenchymal transition (EMT) is a well-known process in fetal 
development and pathologic cancer progression, but a debated phenomenon in 
human kidney fibrosis (Zeisberg, Duffield 2010). Most studies of EMT in renal tissue 
have been performed in animal models or adults. We used two mesenchymal 
markers, vimentin and α-SMA, to study the prognostic value for early fibrogenesis. 
PSGL-1 was selected to detect interstitial inflammation, and collagen IV to visualize 
fibrosis. Neither immunohistological markers nor Banff chronic scores were found to 
be significant risk factors for poor graft function in our cohort. The results were 
similar with a single marker or when added up to a combined score. 
 
Inflammation in biopsy indicates that the underlying disorder is actively progressing, 
and thus has adverse effects on graft survival (Sellares et al. 2011). Retrospective 
analysis of post-transplant DSA was available from fifty-two patients, one-fourth 
(13/52) of whom had detectable post-transplant DSA. These occasionally timed 
samples showed no significant association between DSA and simultaneous 
histopathology or biomarker scores (data not shown). Interstitial inflammation was 
studied with PSGL-1, a membrane-bound molecule and an important ligand for 
endothelial selectins on leucocytes enabling leucocyte recruitment (Ley 2003). We 
found a significant correlation between PSGL-1 expression and Banff inflammation 
(i) score, and IF/TA scoring. This demonstrated simultaneous processes of 
inflammation and fibrosis, a harmful combination for graft survival (Mannon et al. 
2010, Mengel et al. 2009, Park et al. 2010, Sellares et al. 2011). Even low-grade 
inflammation alone shows adverse effects on graft function, especially when 
persistent (Mengel et al. 2007).  
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Early fibrogenesis is detectable as vimentin expression in tubular epithelial cells (de 
Matos et al. 2010, Kers et al. 2010, Xu-Dubois et al. 2013). The expression in 
glomeruli, arterioles and interstitial fibroblasts is normal, whereas in tubular 
epithelial cells (TECs) this intermediate filament protein is a marker of mesenchymal 
phenotype (Muramatsu et al. 2004, Hertig et al. 2008). While vimentin might be 
detectable already at the time of transplantation in TECs, the harmful de novo 
expression increases with time and associates with poor graft function (Kers et al. 
2010, Hertig et al. 2008). We found the highest expression of tubular vimentin at 3 
months post-RTx, but only a weak association with IF/TA score and no prognostic 
value for long-term GFR. A high vimentin score predicted poor GFR at 3–4 years 
post-RTx only at 1.5-year biopsies, but this was not confirmed by multivariable 
analysis. In fact, multiple confounders with different mechanisms and effects take 
part in the allograft injury (Alexander et al. 2007), which supports the idea of adding 
biomarkers to predictive panels. 
 
The development of allograft injury may also be visualized by another mesenchymal 
marker, α-SMA. It is strongly expressed in myofibroblasts (Roberts et al. 1997, 
Goumenos et al. 1994), and the interstitial expression of α-SMA associates with 
collagen depositions in the interstitium and vimentin expression in TECs (de Matos 
et al. 2010, Kers et al. 2010, Vitalone et al. 2008). We found that α-SMA expression 
associated with fibrosis, but not independently with long-term graft function. Also, 
increased collagen IV expression was demonstrated in the areas of fibrosis in which 
the extracellular matrix accumulates into the interstitium. Deposition of different type 
of collagens, including collagen type IV, is characteristic for these areas (Yan et al. 
2010).  
 
In theory, combining different immunohistochemical biomarkers, which demonstrate 
different mechanisms of allograft injury, could add the ability to predict poor graft 
function. However, we found that the most important predictor of graft function was 
the progression of fibrosis. Although biomarker expression might precede the 
appearance of visual IF/TA, the predictive value of molecular markers is always less 
prominent than the effect of structural change with a simultaneous loss of graft 
function. Due to the multifactorial process of chronic allograft injury, no panel of 
clinically relevant biomarkers is yet validated for routine use (Stegall, Borrows 
2015).  
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6.3 Anemia and graft function: Cause or consequence? (III) 
Inadequate management of post-transplant anemia may impair the long-term 
survival. Anemia is a risk factor for cardiovascular disease (CVD), which increases 
the risk for mortality among pediatric transplant recipients (Kaidar et al. 2014, 
Silverstein 2004). Similarly, adult renal transplant patients with anemia are shown to 
have an additional 25% risk for renal graft loss (Winkelmayer et al. 2006) and 
increased rate of mortality (Molnar et al. 2007, Chhabra et al. 2008). Interestingly, 
even partial correction of Hb levels might improve the health-related quality of life 
and physical functioning (Johansen et al. 2010) and prolong the long-term graft 
function and survival (Yabu, Winkelmayer 2011, Reindl-Schwaighofer, Oberbauer 
2013). 
 
The reported rates of PTA reach 31% in Australia (Chadban et al. 2007) and 42% in 
Europe (Molnar et al. 2011a). In our pediatric study cohort, the rates of PTA at 1 
and 5 post-RTx years were 55% and 44%, respectively. Early PTA within the first 
post-RTx year involved up to 87% of patients, which is in accordance with a 
reported 91% prevalence of immediate (first 3 months) PTA in adults (Poesen et al. 
2011). Our findings of decreasing frequency of anemia with time are in line with 
other reports suggesting that Hb levels increase with age and time since RTx 
(Krischock et al. 2016). 
 
Moderate anemia was a common finding in patients at all ages in our study cohort. 
The study of Yorgin et al. reported a lower frequency of early anemia in patients 
less than 2 years at RTx compared to older children, and speculated that an adult 
size kidney graft possibly produces relatively more EPO and clears uremic toxins 
more effectively in a small recipients compared to older children (Yorgin et al. 
2002a). However, we found the youngest children to be more anemic due to the 
high prevalence (76%) of young CNF patients. CNF patients in general had lower 
Hb levels already early after RTx, possibly due to nephrectomy prior to the 
operation. Severe anemia (Hb < 100 g/L), in contrast, was infrequent (range 3-9%) 
after the first few years. Similar frequencies (2–14%) of severe anemia were 
reported in both, adult (Vanrenterghem et al. 2003, Molnar et al. 2011a) and 
pediatric cohorts (Al-Khoury et al. 2006, Mitsnefes et al. 2005).  
 
An unresolved question remains: what causes anemia in RTx patients? The 
hemoglobin levels of RTx patients are lower compared to general population, which 
highlights the role of transplant-associated factors (Chadban et al. 2007). Iron and 
EPO availability are the main regulators of erythropoiesis, and insufficient EPO 
production from renal peritubular fibroblasts leads to renal anemia. In normal 
kidneys, renal tissue hypoxia stimulates the production of EPO, but among CKD 
patients, pro-inflammatory cytokines have a negative effect on this regulation 
(Jelkmann 2011, Jelkmann 1998). Serum EPO levels were reported to be low in 
pediatric RTx recipients with anemia (Yorgin et al. 2002a), which is contrary to our 
findings of rather increased levels of EPO. However, the EPO values in our study 
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were close to the reported normal reference (6-32 mIU/mL) (Jelkmann 2011). EPO 
levels were inversely associated with Hb, but unrelated to GFR, similarly to the 
results reported by Sinnamon et al. (Sinnamon et al. 2007). A correlation between 
EPO and 51Cr-EDTA clearance was not detected in CKD patients, either, regardless 
of anemia (Mercadal et al. 2012). These findings speak against the idea that 
impaired EPO production alone could explain the high frequency of post-transplant 
anemia after RTx. 
 
Iron deficiency induces microcytic and hypochromic anemia. Iron deficiency has 
been reported in up to 33 % of pediatric RTx patients (Kausman et al. 2004, Yorgin 
et al. 2002a), when defined as ferritin levels of <100 μg/L (ng/mL) and TSAT of 
<20% (Galutira, Del Rio 2012). The use of serum iron, transferrin saturation, and 
ferritin is common, although problematic due to the large variety of cut-off levels and 
the acute-phase reactivity of the ferritin (Horl 2007, Lorenz et al. 2002). In our 
patient cohort, the overall frequency of microcytosis (1.3%) and hypochromia (9 %) 
was low. Hepcidin-25 levels were high in severely anemic samples, suggesting that 
inflammation and limited hepcidin-25 excretion due to reduced GFR were present 
rather than iron deficiency. These findings are consistent with a recent study of 
increased hepcidin-25 levels due to inflammation and poor GFR (Chan et al. 2013).  
 
The myelosuppressive effect of the antimetabolites AZA and MMF is suggested to 
increase the risk of late PTA (Mitsnefes et al. 2005, Vanrenterghem et al. 2003, 
Yorgin et al. 2002b, Al-Uzri et al. 2003) although some studies lack clear evidence 
of a direct association (Pascual et al. 2013, Chhabra et al. 2008). In our study, 
patients transplanted in the 1990s received a constant dose of AZA (1 mg/kg/day), 
whereas MMF was used in only a minority of the patients. However, our data 
suggested that general myelosuppression was an infrequent cause of PTA. 
 
In kidney graft biopsies, fibrosis and inflammation are characteristic findings before 
the loss of graft function. Inflammation, together with decreased oxygen delivery to 
the graft, may lead to progressive tubulointerstitial hypoxia and fibrosis (Fine, 
Norman 2008). On the other hand, fibrosis may impair the production of EPO by the 
peritubular cells. We found an association between Hb levels and IF/TA-findings in 
control biopsy samples. Interestingly, low Hb levels preceded the biopsy findings, 
suggesting that anemia may also partly worsen the graft histology. 
 
The recent ESPN/ERA-EDTA registry data of over 3,600 pediatric RTx patients 
demonstrated that low Hb levels associated with worse eGFR and increased risk for 
graft failure (Krischock et al. 2016). Our longitudinal study showed a similar, up to 
23% decrease in GFR among anemic recipients during the follow-up, verifying the 
previous cross-sectional observations. More importantly, the low Hb levels seemed 
to predict decreased subsequent GFR levels, which is in accordance with a recent 
report on adults showing that low Hb levels at one month were an independent 
prognostic factor for later graft loss (Pascual et al. 2013). The small number of graft 
losses did not allow us to analyze the effect of low Hb level on graft survival.   
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6.4 Low-grade inflammation and long-term prognosis (III) 
 
Low-grade inflammation is a common complication of CKD and transplantation per 
se in RTx recipients. Inflammation is a pathogenic mechanism of CAI and a risk for 
graft-related complications. CAI induces the infiltration of inflammatory cells to the 
graft, and the sustained production of cytokines and pro-inflammatory molecules 
leads to chronic inflammation.  
 
Chronic inflammation is known to induce anemia and atherosclerosis, and to impair 
graft function (Cottone et al. 2007). Pre-transplant CRP levels have been 
associated with biopsy-proven allograft nephropathy (Fink et al. 2002), and post-
transplant hsCRP levels have been shown to predict cardiovascular events and 
mortality in RTx recipients (Abedini et al. 2009). Both IL-6 and hsCRP levels are 
important risk factors for long-term graft outcomes in adults (Dahle et al. 2011). 
 
In our pediatric cohort, IL-6 and hsCRP levels were measured repeatedly (median 6 
measurements/patient) over time to investigate the association between low-grade 
inflammation and graft function. Interestingly, inflammation markers fluctuated only 
slightly over time, demonstrating the peak levels of IL-6 at 1 month and hsCRP at 2 
years post-RTx. In our cohort, serum hsCRP levels were low in most anemic 
patients and showed only a weak inverse correlation with the Hb levels. IL-6 levels 
correlated with hsCRP but not with hepcidin-25 or Hb levels. The longitudinal follow-
up data on inflammatory markers did not favor the idea that low-grade inflammation 
would significantly induce the rate of anemia in pediatric RTx patients. Moreover, 
we found a positive correlation between hsCRP and EPO level, which is in 
agreement with the previous findings that inflammation may independently stimulate 
EPO production in CKD patients (Mercadal et al. 2012). 
 
The markers of low-grade inflammation correlated poorly with either concomitant or 
subsequent graft function. A marker of increased red blood cell aggregation, ESR, 
increased significantly along CKD stages with decreasing GFR. The role of ESR in 
transplantation requires future studies to determine the ability of ESR to identify 
high-risk patients who would benefit from more cautious post-transplant monitoring. 
However, hsCRP and IL-6 showed no similar clear association with graft function, 
and the effect of low-grade inflammation on long-term graft function remained 
modest in multivariable analyses. This might reflect the high prevalence of low-
grade inflammation among all RTx recipients and the multifactorial effect of 
inflammation on long-term prognosis.  
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6.5 Clinical characteristics of BKPyV infection (IV) 
Polyomavirus infection is an important risk factor for allograft injury (Acott, Hirsch 
2007). Over 80% of healthy children and adolescent are seropositive for BKPyV, 
and this reflects the high frequency of primary infections during childhood (Egli et al. 
2009). BKPyV infection is asymptomatic and harmless for immunocompetent 
individuals, although the virus persists in the renoepithelial cells after the primary 
infection (Rinaldo et al. 2013).  
 
One important question is how to identify patients at the highest risk for BKPyV in 
the early period. In pediatric studies, recipient seronegativity is a significant risk 
factor for BKPyVAN (Smith et al. 2004, Ginevri et al. 2003), although seropositivity 
does not protect the recipient from reactivation. We found BK viremia in 9 (20%) 
patients who showed a tendency for decreased GFR during the follow-up. Viral 
BKPyV replication in plasma occurred at a median of 6 months post-RTx.  
 
High-risk patients would benefit from individualized selection and early adjustments 
of initial immunosuppression, although the continuous balancing between the risk 
for acute rejection and over-immunosuppression persists. Recent studies describe 
how the use of tacrolimus directly contributes to BKPyV replication, and thus 
increases the risk for BKPyV infection, whereas the use of CsA shows opposite 
effects (Hirsch et al. 2016, Hirsch et al. 2013).  
 
Early BKPyV replication during the first weeks after transplantation might be donor-
derived and increase further the risk for subsequent viremia and BKPyVAN (Saundh 
et al. 2013). The importance of donor-derived transmission is highlighted in a recent 
study of Schwarz et al. (Schwarz et al. 2015), where they demonstrate the 
dominance of the donor’s BKPyV subtype, and suggest that pretransplant urinary 
BKPyV shedding is a major risk factor for posttransplant infection. However, neither 
recipient nor donor evaluation includes the routine serology for BKPyV. Instead, 
post-transplant BK viruria and viremia are often monitored according to protocols 
(Hirsch et al. 2014), as both BK viruria and viremia precede the progression of 
BKPyVAN. Overall, BKPyVAN affects 3–8% of the pediatric kidney recipients (Acott, 
Hirsch 2007). We found three patients with SV40 positivity in biopsies, a diagnostic 
sign of PyVAN. Two of these patients had BK viremia, and one demonstrated an 
uncommon case of JCPyV-associated nephropathy (JCVAN) (Lautenschlager et al. 
2014). Two grafts were lost, both due to ABMR with DSAs in blood and clear C4d 
positivity in biopsies. Both patients were adolescents at the time of operation. 
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6.6 Methodology: advantages and pitfalls 
 
Pediatric patients are a unique study population to evaluate the role of biomarkers 
in chronic allograft injury, as this patient cohort lacks many common confounders 
(e.g. hypertension and advanced age) seen in adult recipients. The strengths of our 
studies were the longitudinal study design, a relatively large study cohort of 
pediatric patients, and annual GFR assessment by 51Cr-EDTA clearance during up 
to 10 years of follow-up.  
 
Limitations were identified due to the retrospective nature of the study. The lack of 
pre-transplant sera in studies I and IV limits the interpretation of the role of dnDSA. 
In addition, the solid-phase assay used is a qualitative detector of DSAs. 
Quantitative comparison of different DSA levels could be more specific (Reed et al. 
2013). The other shortcomings of the Luminex technology are overdetection, 
unclear cut-off value for MFI to define DSA positivity, and the gradual decrease in 
antibody reactivity.  
 
Immunohistochemistry was used to increase the diagnostic ability of invasive 
percutaneous core needle biopsies to characterize the allograft status. The biopsy 
procedure is safe, but sampling errors, inter-observer and interpretation variability 
challenge the accuracy of biopsy results. The major limitation at the time of study II 
was that we could not reliably associate biomarker findings with ABMR, as many of 
the biopsy samples were collected before the routine measurements of DSA and 
availability for the routine immunohistochemistry of C4d. Unfortunately, the staining 
of the paraffin-embedded samples for C4d afterwards was not reliable, as the 
grading of paraffin-embedded samples is unspecific and less sensitive than 
immunofluorescence for frozen sections (Seemayer et al. 2007). In addition, 
anemia-related factors, such as folate and vitamin B12 levels, were not available for 
analysis in study III. Also, the lack of iron status assessments limits the 
interpretation of the causality.  
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6.7 Future challenges and opportunities 
Noninvasive biomarkers are studied to identify potential mechanisms and new 
diagnostic and therapeutic targets of chronic allograft injury. Early detection of 
clinical problems is important when the aim is to focus on therapeutic interventions 
in time. The use of biomarkers as surrogate end points decreases the time interval 
needed for sufficient outcome frequencies in long-term studies and enables the 
determination of efficacy. Recent approaches to promote long-term graft survival 
include individualized therapy and pre-emptive transplantations. The goal is to 
identify biomarkers that are sensitive to identify functioning grafts that will fail but 
could be rescued with early interventions. It is important to understand the 
mechanisms and features of chronic allograft injury and thus to develop and focus 
on early interventions for the right patients.  
 
Recent studies with microarray analyses propose that the role of progressive CNI 
toxicity might be overestimated.  Minimization strategies of immunosuppression 
may actually increase the risk for ABMR, and the role of ABMR in allograft injury 
might be underestimated (Halloran et al. 2014). Noninvasive microarray tests are 
powerful and diagnostic, but their incorporation into clinical transplantation requires 
distinct validation.  
 
To date, renal function, DSAs, and graft histology are examples of biomarkers used 
as surrogate end points in clinical practice. Novel biomarkers are still often relatively 
non-specific and impractical, although gene expression methods enhance 
diagnostic accuracy and may add predictivity when combined with histology 
(Halloran et al. 2013). In the ongoing prospective IVIS trial, virus-specific T cells are 
successfully used as novel biomarkers of overimmunosuppression in pediatric RTx 
recipients (Ahlenstiel-Grunow et al. 2014). A combination of novel methods could be 
used as a molecular microscope to identify high-risk recipients before the early 
signs of graft failure (Loupy et al. 2014). 
  
Future developments in the field of biomarkers in kidney transplantation include 
novel analytical methods for self-monitoring of individual drug levels. This would 
enable more customized therapies of immunosuppressants with a narrow 
therapeutic window and significant inter-individual variability. Although tools and 
technologies are already available to model disease pathophysiology, molecular 
signatures are far from the predictive biomarkers. Financial and collaborative efforts 
of different biosciences are needed to transfer the benefits of the complex 
technologies into clinical use.
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7 CONCLUSIONS 
The present studies focus on biomarkers that could identify patients at risk for 
chronic allograft injury.  
 
Study I showed that circulating HLA antibodies were rather common in pediatric 
RTx patients, and DSA was detectable in one-third of the patients. DSA reacted 
mainly against class II antigens, but did not predict significantly worse graft function 
at the time of sampling or later on.  
 
Study II demonstrated that biomarker expression associated with IF/TA lesions, 
which increased during the first three years post-RTx in protocol biopsies. Intense 
staining of collagen IV and vimentin associated with poor graft function, similarly to 
IFTA score. Histochemical biomarkers did not significantly add the ability to predict 
future graft function when compared to routine histopathology.  
 
Study III described the correlation of anemia and inflammation with graft function 
over time. Both anemia and low-grade inflammation were common findings even 
years after RTx. Anemia associated with poor graft function, which was not 
explained by distinct inflammation or erythropoietin deficiency.  
 
Study IV characterized the findings of BK viremia in pediatric RTX recipients. BK 
viremia and polyomavirus-associated nephropathy were rather uncommon, but 
patients with BK viremia showed a tendency for poor long-term graft function.  
 
Development of chronic allograft injury is a multifactorial process with several 
immunological and non-immunological components that influence the allograft 
histopathology and function. Based on the results of this thesis, biomarkers of 
different pathophysiological mechanisms may identify patients at risk for poor 
kidney graft function. Patients with activated immune response or altered 
biochemical parameters require thorough evaluation, as no biomarker to date is well 
established to characterize the high-risk recipients of CAI.
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